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ABSTRACT 
 
Extensive crosstalk between phosphorylation and O-GlcNAcylation is involved in 
regulating insulin signaling. In addition, many of the key regulators of insulin signaling have 
been shown to be O-GlcNAcylated. In this study, we first explored the crosstalk between 
phosphorylation and O-GlcNAcylation globally, and then focused on an upstream signaling 
regulator key to insulin signaling, insulin receptor substrate 1, IRS1. Through regulating 
cellular O-GlcNAcylation levels in differentiated adipocyte 3T3-L1 cells by specific OGT 
and OGA inhibitors, we measured the affects of O-GlcNAcylation on the phosphorylation 
status of key molecules. We observed that O-GlcNAcylation regulates the flux through the 
two main divergent cellular pathways of insulin signaling, one regulating glucose metabolism 
and the other regulating cellular proliferation via MAP kinase. Decreased O-GlcNAcylation 
was associated with increased glucose utilization, and increased O-GlcNAcylation was 
associated with increased insulin-induced cellular proliferation pathways. Since IRS1 is early 
in the insulin signaling pathway and is both highly O-GlcNAcylated and highly 
phosphorylated, we focused on the crosstalk of those two PTMs on IRS1. The 
phosphorylation spectrum of IRS1 revealed by 2D electrophoretic analyses, partially 
explained why decreased O-GlcNAcylation facilitated glucose uptake. Two new O-
GlcNAcylation sites were mapped through CID/ETD mass spectrometry. With help of 
protein truncation and site mutagenesis techniques, we propose a mechanism suggesting that 
the O-GlcNAcylation of Ser635, may be a negative regulator of the C-terminal O-
GlcNAcylations on IRS1. Since C-terminal O-GlcNAcylation of IRS1 inhibits binding with 
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PI3K, Ser635 O-GlcNAcylation, unlike O-GlcNAcylation at other sites on IRS1, is thus an 
activator for PI3K/AKT signaling. 
 
Dissertation Advisor: Gerald W. Hart, Ph.D.  
Dissertation Reader: Guang William Wong, Ph.D. 
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CHAPTER ONE 
SITE-SPECIFIC INTERPLAY BETWEEN O-GLCNACYLATION AND 
PHOSPHORYLATION IN CELLULAR REGULATION 
by 
Ping Hu, Shino Shimoji-Krishnan and Gerald W. Hart 
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O-linked β-N-acetylglucosamine (O-GlcNAc) modification of serine/threonine 
residues on nuclear and cytoplasmic proteins is a ubiquitious, rapidly cycling 
monosaccharide. Extensive crosstalk or interplay exists between O-GlcNAcylation and 
phosphorylation, which regulates signaling in response to nutrients and stress. Since its 
discovery, difficulties in detecting and in mapping specific O-GlcNAc sites have limited 
progress in this field. In the past five years, the development of novel O-GlcNAc detection 
and enrichment methods, combined with advances in mass spectrometry, have significantly 
improved our understanding of the functions of O-GlcNAcylation. Global site mapping 
studies have revealed O-GlcNAc’s many interactions with phosphorylation-mediated 
signaling. Despite their intimate and dynamic interplay, the mechanisms regulating O-
GlcNAcylation and phosphorylation are quite different. Phosphorylation is catalyzed by 
hundreds of distinct genetically encoded kinases, each with its own catalytic activity. In 
contrast, in mammals uridine diphospho-N-acetylgucosamine:polypeptide β-N-
acetylglucosamyl transferase (OGT) is encoded by a single highly-conserved X-linked gene. 
However, like RNA polymerase II (RNAP II) and phosphatases, OGT’s protein specificity 
and targeting are determined by its transient associations with many other regulatory subunits 
to create a multitude of specific holoenzymes. O-GlcNAcase (OGA), the enzyme that 
removes O-GlcNAc, is also encoded by a single highly conserved gene, and is targeted to its 
substrates in a manner similar to OGT. The extensive crosstalk between O-GlcNAcylation 
and phosphorylation represents a new paradigm for cellular signaling. 
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INTRODUCTION 
 
Ser(Thr)-O-linked β-N-acetylglucosamine (O-GlcNAc) is a common posttranslational 
modification (PTM) of nuclear and cytosolic proteins. O-GlcNAcylation was serendipitously 
discovered in experiments designed to detect terminal GlcNAc residues on the surfaces of 
living lymphocytes, but surprisingly nearly all of the O-GlcNAc was found to be on 
nucleocytoplasmic proteins, where dogma said protein glycosylation was absent [1,2] . O-
GlcNAcylation occurs in some bacteria, many protozoa, viruses, filamentous fungi and in all 
metazoans, including plants, but thus far has not been definitively documented in yeast.  O-
GlcNAcylation is distinguished from “classical” glycosylation in the following respects: 1) It 
is nearly exclusively on cytoplasmic and nuclear proteins, compared to the extracellular and 
luminal localization for most other protein-bound glycosyl moieties. 2) O-GlcNAc is 
generally not modified or elongated to more complex structures.  3) Like phosphorylation, O-
GlcNAcylation occurs at substoichiometric amounts and rapidly cycles on and off 
polypeptides at different rates at specific sites in response to different physiological stimuli, 
such as hormones, growth factors, and mitogens[3-6] (more in review[7]).  
     Uridine diphospho-N-acetylgucosamine:polypeptide β-N-acetylglucosamyl 
transferase (OGT) and β-D-N-acetylgucosaminidase (OGA) are the paired enzymes 
responsible  for the addition and removal of O-GlcNAc, respectively. Although O-
GlcNAcylation has many properties similar to phosphorylation, the two post-translational 
modifications are regulated very differently. Phosphorylation is determined by hundreds of 
specific kinases, each encoded by a distinct gene. In contrast, both OGT and OGA are 
encoded by a single highly conserved gene in animals (two alleles of OGT in plants [8].), 
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which contains their catalytic centers and numerous protein-protein interaction domains [9-
11]. Like RNAP II, phosphatases [12] and other enzymes, OGT’s and OGA’s protein 
specificity is mostly determined by its transient interactions with many binding partners to 
form many substrate specific holoenzymes [13,14]. The OGT catalytic subunit also has 
pronounced specificity to peptide sequence around the attachment site, but no absolute 
consensus sequence exists. In addition, OGT’s enzymatic activity is highly responsive to the 
concentration of uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc), the donor 
substrate for O-GlcNAcylation [15].  
     OGT is found in many organisms, from C. elegans, Drosophila, plants to human, 
and shares very high homology among species [7]. The Ogt gene resides on the X 
chromosome near the centromere. Knock-out studies have shown that Ogt is required for the 
viability of embryonic stem (ES) cells and other cells, even in cell culture [16]. Tissue 
targeted Ogt mutations in mice and several cell lines, such as T cell, neuronal cell, 
fibroblasts, using the Cre-loxP recombination system demonstrated that loss of O-
GlcNAcylation results in concomitant loss of cell function and eventually cell death [16].  In 
contrast to plants and mammals, in C. elegans, Ogt knockout, while producing profound 
metabolic changes, such as insulin resistance and abnormal metabolism, does not cause the 
death of the worm. These and other genetic studies support a role for O-GlcNAcylation in 
cellular signaling and insulin resistance [17]. For humans, there are at least three transcript 
isoforms of OGT: 110 kilodalton (kDa) (p110), 78kDa (p78) and 103kDa (p103), with 
variation from 2.5-13.5 tetratricopeptide repeats (TPRs). The catalytic p110 subunit can form 
either a homodimer or heterotrimer with p78 in the cytoplasm and nucleus depending on cell 
type, while p103 is localized to the mitochondria [7,9,18]. OGT’s catalytic subunit is 
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composed of two separate domains. Its N-terminus contains TPRs, which mediate protein-
protein interactions, thus functioning in OGT substrate recognition and multimerization. The 
C-terminus of p110 has the catalytic domain, possessing glycosyltransferase activity [19,20]. 
Structural analysis of 11.5 of N-terminus TPR domain shows a right-handed superhelix of 
about 100 Å long and 35Å wide, which likely provides for substrate binding on its concave 
surface [21]. The crystal structure of a bacterial orthologue of human OGT (hOGT), from 
Xanthomonas campestris OGT (XcOGT) shows that OGT has a conserved UDP-GlcNAc 
binding pocket. This structure also shows that the last few TPRs are, closely associated with 
C-terminal active site, forming an elongated, continuous groove from the donor substrate 
binding site to the end of the TPR superhelix [22,23]. Molecular modeling of the bacterial 
structure and the mammalian TPR-repeat structure strongly supports the structure proposed 
for the mammalian OGT [13-15].  
     OGA was initially identified as hexosaminidase C, with β-linked GlcNAc 
substrate specificity, neutral pH optima, and mainly a cytosolic localization, unlike lysosomal 
hexosaminidases [24-26]. Strikingly, Oga knockouts in C.elegans showed similar metabolic 
defects as the ogt knockouts, such as elevated stores of glycogen, and decreased lipid storage. 
This finding suggests that O-GlcNAc cycling rates and not its absolute stoichiometry may be 
important in its regulation of cellular metabolism. Human OGA (hOGA) is a 92 kDa 
bifunctional protein, its N-terminus contains O-GlcNAc hydrolase activity, and its C-
terminus bears a putative histone acetyltransferase (HAT) domain. Caspase-3, a cysteine-
aspartic protease that serves as the “executioner protease” in apoptosis, cleaves these two 
domains during apoptosis without affecting the O-GlcNAc hydrolase catalytic activity 
[27,28].  hOGA catalyzes O-GlcNAc hydrolysis using a substrate-assisted mechanism, which 
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requires the involvement of the 2-acetamido group of GlcNAc as the nucleophile [29]. 
Similar catalytic mechanisms were also confirmed on bacterial OGA orthologues from 
Clostridium perfringens NagJ and B. thetaiotaomicron BtGH84 [30,31].  
 
O-GLCNACYLATION IS A NUTRIENT AND STRESS SENSOR 
 
As stated above, UDP-GlcNAc, the immediate donor substrate for O-GlcNAcylation, 
is a terminal product of the hexosamine biosynthetic pathway (HBP) (Figure 1). This sugar 
nucleotide is second only to adenosine triphosphate (ATP) in abundance of high energy small 
molecules in cells.  When HBP flux changes, UDP-GlcNAc levels also change rapidly, 
altering the extent of O-GlcNAcylation of many proteins. HBP flux and UDP-GlcNAc 
availability are affected directly by many different nutrients, such as glucose, fatty acids, and 
amino acids. Exogenously added glucosamine is efficiently ‘salvaged’ by cells, and small 
amounts can dramatically increase UDP-GlcNAc pools in cells. When glucose enters cells, 
besides being used for glycogen synthesis or glycolysis, a portion (2-5%) is converted to 
UDP-GlcNAc [32]. Free fatty acids also increase HBP flux by inhibiting glycolysis, resulting 
in elevated fructose-6-phosphate levels. Acetyl-CoA, produced by fatty acid metabolism, 
serves as the donor for the acetylation of glucosamine in the formation of UDP-GlcNAc. L-
glutamine: D-fructose-6-phosphate aminotransferase (GFAT) is the key rate-limiting enzyme 
of the HBP. GFAT converts fructose-6-phosphate to glucosamine-6-phosphate, using 
glutamine as the nitrogen donor. GFAT is by passed by glucosamine, which enters directly 
into the HBP by being phosphorylated to form glucosamine-6-phosphate [33]. Ob/ob mice, 
which lack of leptin, a hormone that regulates nutrient uptake, have elevated GFAT activity 
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and increased UDP-GlcNAc levels in muscle. Leptin mRNA and protein expression are 
upregulated by high levels of nutrients. UDP-GlcNAc levels are increased in tissues by 
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Figure 1. HBP and O-GlcNAcylation. In addition to glycolysis and glycogen synthesis, 2-
5% of cellular glucose is processed through HBP. GFAT mediated conversion of fructose-6-
phosphate to glucosamine-6-phosphate is the rate-limiting step of HBP. The presence of 
elevated FFA has been linked to inhibition of glycolysis and elevated glucose flux through 
HBP. UDP-GlcNAc is the end product of the HBP. OGT catalyzes the transfer of O-GlcNAc 
from UDP-GlcNAc onto the hydroxyl moiety of serine or threonine residues,while OGA 
catalyzes the removal of the sugar. Addition of glutamine or glucosamine elevates global O-
GlcNAcylation.  
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The substrate specificity of OGT, as well as its enzymatic activity are regulated by 
different levels of UDP-GlcNAc [15]. In hyperglycemia, elevated HBP flux cause increased 
O-GlcNAcylation on specific insulin signaling molecules, such as Akt, insulin receptor 
substrate 1 (IRS1), and others, to negatively regulate the insulin pathway. Excessive O-
GlcNAcylation of insulin signaling molecules results in less insulin-stimulated glucose 
transport [33].  
     Hyperglycemia and hyperlipidemia also affect transcription by increasing the O-
GlcNAcylation of transcription factors, such as Sp1. For example, the saturated fatty acid, 
palmitate, which causes increased HBP flux, increases Sp1’s DNA binding activity, as well 
as its transcription activity by elevating its O-GlcNAcylation state [36].  
     O-GlcNAcylation is also a sensor of cellular stress. Multiple forms of stress 
increase glucose uptake and thus HBP flux and concomitantly increase UDP-GlcNAc 
concentrations, leading to rapid increased global O-GlcNAcylation. Heat shock protein 70 
(Hsp-70), a key chaperone protein, which protects cells from stress, is an endogenous O-
GlcNAc binding lectin [37]. Many different stresses, such as oxidative, osmotic, UV, 
ethanol, and heat shock induce rapid and global increased O-GlcNAcylation. Increased O-
GlcNAcylation induced by thermal stress occurs rapidly and returns back to basal levels after 
removing the stress. Thermal stress increases OGT’s enzymatic activity but does not increase 
its expression. In contrast, OGT expression is increased by ethanol treatment or by osmotic 
stress. Ogt knockout through Cre-LoxP in mouse embryonic fibroblasts cells (MEFs) or 
knockdown of OGT by using RNA interference (RNAi) in mouse neuroblastoma cells 
(Neuro-2A) both decreased thermotolerance. Artifically increasing cellular O-GlcNAc levels 
by pharmacological inhibiting OGA activity, using the inhibitor, O-(2-acetamido-2-deoxy-D-
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glucopyranosylidene) amino-N-phenylcarbamate (PUGNAc), resulted in increased 
thermotolerance. This protective effect of O-GlcNAcylation on thermal stress is partially 
explained by elevating Hsp70 and Hsp40 expression [38], chaperon complex of these two 
proteins is well known as heat protector in mammalian cells [39].   
 
     Paradoxically, despite lower UDP-GlcNAc and ATP levels, global O-
GlcNAcylation is strikingly increased when neuronal cells are deprived of glucose. When 
Neuro-2a cells are deprived of glucose, increased OGT mRNA and protein expression were 
observed. OGT’s targeting to a population of substrate proteins, rather than an increase in its 
catalytic activity was found. OGT’s increased activity towards this glucose-deprivation 
dependent population of proteins in Neuro2a cells was dependent upon AMP-activated 
protein kinase (AMPK) and mitogen-activated protein kinase (MAPK)/p38 [13]. However, in 
human hepatocellular carcinoma cells (HepG2), glucose-deprivation dependent elevation of 
O-GlcNAcylation results mainly from increased OGT mRNA and protein expression, as well 
as decreased OGA expression, while not kinase activity dependent [40,41]. Glucose 
deprivation increases O-GlcNAcylation in human non-small cell lung carcinoma A549 cells, 
by yet a different mechanism. In A549 cancer cells, glucose deprivation results in increased 
HBP flux as well as increased UDP-GlcNAc levels. The source of glucose driving the 
increased HBP flux is from increased glycogen phosphorylase activity, the rate-limiting step 
in mobilizing glycogen. In A549 cancer cells glucose deprivation also results in increased 
GFAT activity. In addition, glucose deprivation in A549 results in higher OGT enzymatic 
activity and lower enzymatic activity for OGA without changing OGT and OGA expression 
levels [42]. The different mechanisms elevating O-GlcNAcylation in response to glucose 
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deprivation may result from the distinctly different mechanisms regulating energy 
metabolism in these different cell-types.  Thus, there are complex and intimate relationships 
between nutrient status, stress status and O-GlcNAcylation. O-GlcNAcylation not only 
responds to cell nutrient and stress status, but also regulates the cell’s reactions to variations 
in nutrients and stress.  
 
DETECTION AND SITE MAPPING OF O-GLCNAC 
 
     O-GlcNAcylation can be detected by using pan-specific anti-O-GlcNAc antibodies 
(CTD 110.6, RL2, HGAC 85) or lectins (succinylated Wheat-Germ Agglutinin, sWGA). 
CTD 110.6 is an IgM monoclonal antibody produced using chemically synthesized O-
GlcNAcylated peptide based upon a single repeat of the RNAP II carboxyl terminal domain 
(CTD) motif as the antigen [34]. RL2 is an IgG monoclonal produced using nuclear pore 
protein complex fractions as the antigen. HGAC 85 is a monoclonal antibody made against 
streptococcal group A polysaccharide, which recognizes O-GlcNAc [43]. All of these 
antibodies bind with relatively low affinity and favor the detection of highly abundant O-
GlcNAcylated proteins or those with clustered O-GlcNAc moieties. While mostly 
recognizing O-GlcNAc, these antibodies differ in their dependency upon peptide structure 
and bind different subsets of O-GlcNAcylated proteins [44,45]. Recently, several O-GlcNAc-
peptide specific monoclonal antibodies have been described, which may prove valuable in 
further defining the biological roles of O-GlcNAcylation [46]. The lectin, sWGA, is able to 
recognize any terminal GlcNAc, including those on N-glycans, O-glycans or O-GlcNAc. 
Regardless of which probe is used, additional controls, such as inhibition of binding by 
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excess GlcNAc, prior treatment with hexosaminidase, or ‘capping’ the epitope with 
galactosyltransferase should be used [34] to validate specificity. 
     As with any post-translational modification, mapping the attachment site(s) is a 
prerequisite toward understanding the modification’s biological functions. Site mapping  O-
GlcNAcylation is very difficult due to its special characteristics: 1) O-GlcNAcylation usually 
has low stoichiometry at each site on proteins. For example, stoichiometry of O-
GlcNAcylation on α-crystallin, a structural protein in the eye lens, is less than 2% [47,48]. 2) 
In mass spectrometry, the presence of even a small proportion of unmodified peptide ions 
severely suppresses ionization of O-GlcNAcylated peptides. 3) The β-linkage between O-
GlcNAc moiety and Ser/Thr is labile. Upon fragmentation by standard collision induced 
dissociation (CID), the glycosidic bond breaks first, resulting in poor fragmentation of the 
glycopeptide and loss of any site information. With the development of sample enrichment 
methods and new mass spectrometry (MS) fragmentation methods, such as electron capture 
dissociation (ECD) or electron transfer dissociation (ETD), it is now possible to map and 
quantify both O-GlcNAc and phospho-sites simultaneously in complicated samples using 
relatively limited amounts of protein [49].  
 
EARLY APPROCHES TO MAP O-GLCNAC SITES 
In early studies, mapping O-GlcNAc sites was a tedious and time-consuming process, 
often taking nearly one-year. In these early studies, O-GlcNAc site mapping was achieved by 
first tagging the O-GlcNAc protein or peptide by enzymatically attaching a [3H]-galatose, 
using bovine milk β-1,4-galactosyltransferse (GalT1) [1].  Multiple rounds of reverse phase 
high performance liquid chromatography (RP-HPLC) of tryptic peptides were then used to 
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obtain pure radiolabeled glycopeptides. Automated Edman degradation was used to sequence 
the peptide, and manual Edman degradation was used to determine which residue contained 
the radioactivity [50]. Several O-GlcNAc sites were mapped in this way, such as Thr48 and 
Thr431 on neurofilament M (NF-M), Thr21 and Ser27 on NF-L [51,52]. Sites on estrogen 
receptor, as well as synapsin I were also mapped via this method [53-55]. However, this 
method had many problems: 1) It contains too many steps and requires expensive radioactive 
sugar nucleotide. 2) Many rounds of HPLC and Edman degradation are needed to 
definitively identify the major O-GlcNAc sites on a single protein. 3) The overall procedure 
was time consuming and difficult. 4) Large amounts of start sample were required. For 
example, in order to map O-GlcNAc sites, at least 10 picomole of pure, radiolabeled 
glycopeptide was required. Due to sample loss, low stoichiometry of O-GlcNAcylation as 
well as limits in detecting [3H]-galatose, typically nanomole to even micromole amounts of 
starting protein were often required.  
 
MAPPING O-GLCNAC SITES ON RECOMBINANT OR IN VITRO EXPRESSED 
PROTEINS 
     It often is difficult to obtain enough of a low abundance endogenous regulatory 
protein, such as a transcription factor, to map O-GlcNAc sites, even with the best methods 
currently available. Three approaches have proven useful, at least as a starting point: 1) For 
low abundance proteins where DNA is available, the protein can be transcribed and 
translated in a reticulocyte lysate system, which efficiently O-GlcNAcylates nascent proteins 
[56]. Lectin affinity chromatography on sWGA is then used to detect O-GlcNAcylation 
[55,57,58]. 2) Overexpression of the protein in E. coli, which does not O-GlcNAcylate 
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proteins, allows for production of a polypeptide substrate, which can be O-GlcNAcylated in 
vitro, using recombinant OGT. This approach allows for site-mapping, which can readily be 
confirmed in vivo by site-directed mutagenesis, combined with anti-O-GlcNAc Western 
blotting. 3) Fairly large quantities of in vivo O-GlcNAcylated proteins can be obtained by 
over-expressing affinity-tagged proteins (eg. His, Flag, or glutathione S-transferase(GST))). 
This can be done in either insect cells via baculoviral infection [53,55,59-61] or transfection 
in HEK293 mammalian cells [62-64]. Thus far, sites used for O-GlcNAcylation in these 
model systems are also used in other cell-types. However, putative O-GlcNAc sites need to 
be directly confirmed in the cell type under study, usually via site-directed mutagenesis, or 
by mass spectrometry.  
 
O-GLCNAC ENRICHMENT METHODS 
 
     Using large-scale protein preparation, while mitigating the low stoichiometry of 
O-GlcNAc increases the risk of ion-suppression by non-glycosylated peptides. Therefore, it 
is almost always necessary to purify O-GlcNAcylated proteins or peptides away from the 
unmodified peptides.  
 
IMMUNOAFFINITY/LECTIN BASED ENRICHED METHODS 
The simplest O-GlcNAc enrichment approach is to purify O-GlcNAcylated proteins 
using immunoaffinity or lectin chromatography. O-GlcNAcylated proteins from cell lysates 
are efficiently enriched by both anti-O-GlcNAc antibody affinity chromatography or by 
sWGA affinity chromatography [65-67]. However, both methods favor enrichment of high 
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abundance proteins (eg. nuclear pore proteins) or those with multiple clustered O-GlcNAc 
residues. Low abundance proteins with single or widely separated O-GlcNAc sites are 
difficult to purify using these tools and their binding to the affinity solid support is often 
competed by more abundant or higher affinity O-GlcNAcylated proteins.  
 
METABOLIC IN VIVO TAGGING OF O-GLCNAC FOR ENRICHEMENT (TAGGING-VIA-
SUBSTRATE: TAS)  
     This enrichment method takes advantage of the fact that the cellular machinery 
will take up and use N-azidoacetylglucosamine (GlcNAz) as an alternative substrate to 
GlcNAc. In order to facilitate uptake by living cells, GlcNAz is peracetylated. Upon uptake, 
the peracetylated GlcNAz is rapidly deacetylated by intracellular esterases. GlcNAz enters 
the HBP just like glucosamine, but at lower efficiency, and is converted into UDP-N-
azidoacetylglucosamine (UDP-GlcNAz). UDP-GlcNAz is utilized by OGT, and O-GlcNAz 
is  attached to Ser/Thr sites. The GlcNAz on proteins enables conjugation via Staudinger 
ligation to enrichment tags, such as a biotinylated phosphine [68]. After ligation, the labeled 
sample can be selectively purified using strepavidin/avidin beads. This method was termed 
“tagging-via-substrate approach” (TAS). By using this method, 199 putative O-
GlcNAcylated proteins were identified in Hela cells (human cervical cancer cell line) through 
nano-HPLC-MS/MS [69]. The high affinity between biotin and avidin/streptavidin allows for 
a high degree of enrichment by allowing stringent washes to eliminate nonspecifically bound 
material. The major disadvantage of this approach is the poor efficiency of utilization of the 
GlcNAz by the cells. All of the enzymes in the cellular machinery use their native substrates 
much more efficiently. In addition, high levels of endogenous UDP-GlcNAc that is present in 
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most cells effectively competes for utilization of the UDP-GlcNAz. Further, the sensitivity is 
exacerbated by the usual low stoichiometry of O-GlcNAcylation combined with the relative 
inefficiency of incorporation of the azido sugar. Unfortunately, lowering endogenous UDP-
GlcNAc levels to increase efficiency of GlcNAz incorportaion by any of several means will 
generally also perturb the biological process of interest. Nonetheless, this approach is useful 
for studying O-GlcNAcylation on abundant proteins and perhaps on those where the 
saccharide is most rapidly cycling.  
 
β-ELIMINATION FOLLOWED BY MICHAEL ADDITION (BEMAD/MAP) BASED 
ENRICHMENT 
The O-b-GlcNAc glycosidic linkage is much more alkali labile than O-a-GalNAc or 
O-phosphate. Since O-GlcNAc is very sensitive to b-elimination by alkali, and is very labile 
in the gas phase upon CID fragmentation, early site mapping studies used mild b-elimination 
of O-GlcNAc peptides and the resulting loss of water at the Ser(Thr) attachment site (18 m/z 
loss) to map sites [70]. Later, this method was improved by using Michael addition chemistry 
to attach dithiothreitol (DTT) to the b-eliminated O-GlcNAc sites (m/z increase of 136). This 
method was called BEMAD [65]. BEMAD provided for several advantages: 1) The attached 
DTT moiety is stable to standard MS/MS conditions, such as CID, and modified peptides 
fragment normally. 2) DTT allows for affinity enrichment of modified peptides using thiol-
affinity chromatography. 3) Deuterium containing DTT is readily available allowing for 
comparative semi-quantitative mass spectrometry [65,71,72]. The biggest disadvantage of the 
BEMAD method for site mapping is that it is indirect. In theory, alkali-induced elimination 
of any moiety at a Ser(Thr) residue could result in a false positive assignment as an O-
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GlcNAc site. Therefore, the use of BEMAD for site mapping requires many careful controls 
[71,73,74], and confirmation by independent methods. 
 
CHEMOENZYMATIC ENRICHMENT OF O-GLCNAC PEPTIDES  
     Most recently, chemoenzymatic approaches have been used to tag and enrich O-
GlcNAcylated peptides. A commercially available kit (Click It kit, Invitrogen) has simplified 
the use of this approach. A genetically engineered (Y289L muation) galactosylransferase that 
has a larger donor-substrate binding pocket, is used. The mutant GalT can efficiently transfer 
N-azidoacetylgalactosamine (GalNAz) to the O-GlcNAc moiety [75]. Biotin is then 
quantitatively attached to GalNAz via click chemistry using a copper catalyst [76].  The 
labeled protein /peptide can then be enriched through avidin/streptavidin affinity 
chromatography. Even though this tagging and enrichment method greatly enriches the O-
GlcNAcylated proteins/peptides, the enriched sample is still not suitable for direct MS/MS 
analysis. The tag mass attached to the O-GlcNAc is too big, which results in even more 
severe ion suppression compared with nonenriched O-GlcNAcylated peptide. The biotin 
moiety fragments excessively during MS/MS complicating intepretation of the spectra and 
the saccharide moiety bearing the GalNAz-biotin is still very labile during MS/MS 
fragmentation, preventing direct site mapping. 
The combined use of BEMAD and the chemoenzymatic enrichment does allow for 
direct site mapping and the high specificity of the enrichment gives a much higher 
confidence in the validity of sites idenfified. The combined approaches have been used to 
map O-GlcNAc sites on on vimentin and Calcium/Calmodulin-dependent kinase IV 
(CaMKIV) [64,66].  A complex mixture of human erythrocyte proteins was also analyzed 
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using this the chemoenzymatic enrichment followed by BEMAD, resulting in the 
identification of thirty five O-GlcNAc sites [72]. A similar enrichment method that instead 
uses an UDP-ketogalactose and hydrazide coupling of biotin also works well and has been 
used in cell lysates and brain tissue [77,78].  
 
PHOTOCLEAVABLE BIOTIN (PC-BIOTIN) BASED ENRICHMENT OF O-GLCNAC 
PEPTIDES  
     A major problem with enriching O-GlcNAc using biotin/avidin based affinity 
methods is the difficulty of getting quantitative recovery of the bound glycopeptides. Thus, 
building upon Olejnik’s report of photocleavable biotin reagent [79], a photocleavable biotin-
alkyne reagent suitable for use in O-GlcNAc site mapping was developed [49]. The same 
chemoenzymatic attachment method (described above) is used, but the tagged glycopeptides 
are quantitatively released by a cleavage reaction catalyzed by ultraviolet light (365 nm). A 
major advantage of this method, in addition to its efficiency, is that the released peptides now 
carry a basic aminomethyltriazolyl acetylgalactosamine group, which results in a 3+ or 
higher charge state for the tryptic O-GlcNAc peptides. The charged moiety remaining after 
ultraviolet light cleavage not only facilitates electron transfer dissociation mass spectrometry, 
but also produces diagnostic fragment ions (m/z  of 300.2 and 503.1) allowing detection of 
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ADVANCES IN MASS SPECTROMETRY THAT FACILITATE ANALYSES OF 
O-GLCNAC 
 
     The enrichment methods, described above, have solved the analysis problems 
associated with low stoichiometry and ion suppression by unmodified peptides. In addition, 
the sensitivity of modern mass spectrometers continues to increase dramatically.  
 
COLLISION INDUCED (ACTIVATED) DISSOCIATION (CID/CAD)  
     O-GlcNAc attachment to Ser/Thr is labile.  In CID/CAD, the energy required to 
break the O-GlcNAc linkage is much lower than that required to break peptide bond. 
CID/CAD almost always  results in a neutral loss of the saccharide, which can indicate the 
existence of O-GlcNAclation on the peptide, but provides no site information [80-82]. In 
addition, due to the loss of kinetic energy associated with the neutral loss of the saccharide, 
CID/CAD is generally very poor at producing enough peptide fragmentation of the O-
GlcNAc peptide for sequencing. However, in ion-trap mass spectrometers it is possible to 
perform an MS3 CID/CAD and obtain quality peptide sequence, but only after the sugar is 
lost. In contrast, DTT attached by the BEMAD procedure, is not lost during CID/CAD and 
the DTT-peptides fragment as well as unmodified peptides. A combination of BEMAD and 
CID/CAD, has been used to map sites on synapsin I, nuclear pore complex proteins, actin, 
myosin, and IRS-1 [83,84]. 
 
ELECTRON CAPTURE DISSOCIATION (ECD) AND ELECTRON TRANSFER 
DISSOCIATION (ETD) MASS SPECTROMETRY  
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     Electron capture dissociation (ECD) uses low energy electrons to react with 
peptide cations in the magnetic field of a Fourier transform ion cyclotron resonance (FT-
ICR) mass spectrometer [85]. Unlike CID/CAD mass spectrometry, the O-GlcNAc linkage is 
not broken by ECD of peptide ions [67]. However, the high cost and high level of expertise 
required to operate and maintain FT-ICR mass spectrometers limits their widespread use. 
Recently, an ionization method similar to ECD, called electron transfer dissociation (ETD) 
has been developed which works well in lower cost ion trap mass spectrometers [86,87]. 
During ETD an electron is transferred in the gas phase from a radical anion to a protonated 
peptide to induce cleavage of the Cα-N bond. Like CAD, ETD preserves the O-GlcNAc and 
other peptide modifications, while efficiently fragmenting the peptide. The development of 
ETD is a breakthrough in the detection and analysis of O-GlcNAcylation. ETD mass 
spectrometry has recently been used to map O-GlcNAc on paxillin, a focal adhesion adaptor 
protein, IRS-1 and Forkhead box O1 (FoxO1), and PPARγ coactivator-1 (PGC-1α) 
[14,63,88,89]. By combining ETD with sWGA chromatography enrichment, greater-than 
fifty previously unknown O-GlcNAc sites on murine postsynaptic density proteins were 
mapped [90]. Chemoenzymatic enrichment using a photocleavable biotin tag, combined with 
ETD mass spectrometry, enabled the mapping of over one hundred and forty O-GlcNAc sites 
on proteins involved in the regulation of cell division [91].  
 
 
QUANTITIATIVE ANALYSIS OF O-GLCNAC SITE OCCUPANCY   
 
STABLE ISOTOPE LABELING WITH AMINO ACIDES IN CELL CULTURE (SILAC)  
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     In order to quantitatively compare O-GlcNAc levels on different proteins or at 
different sites, stable isotope labeling with amino acids in culture (SILAC) [92,93] when 
combined with the mass spectrometric methods discussed above, has proven to be a method 
of choice. SILAC was used to test quantitative O-GlcNAcylation changes in COS7 cells after 
only a single kinase, glycogen synthase kinse-3 (GSK-3), was inhibited [91].  Major 
disadvantages of SILAC include the high cost of isotope containing amino acids, and that the 
metabolic incorporation of the labeled amino acids requires living samples, either in culture 
or at the whole organism level.   
 
IN VITRO METHODS FOR ISOTOPICALLY LABELING O-GLCNAC PEPTIDES  
     Recently, two similar in vitro methods have been used for quantitative analysis of 
O-GlcNAcylation by isotopically labeling peptides with different tags [72,94]. One approach 
is “Tandem Mass Tags”(TMT) and the other is “Isobaric Tags for Relative and Absolute 
Quantification”(iTRAQ) [95,96]. Peptides are labeled with different tags, which upon 
tandem mass spectrometry are cleaved into different m/z reporter ions. Each tag introduces a 
unique mass shift for the labeled peptides. The advantage of these tags is that they allow for 
multiplexing, and peptides obtained from tissues or other sources can be efficiently labeled in 
vitro. A similar peptide labeling method makes use of reductive amination to incorporate 
stable isotopes into N-terminal amines and ε-amino groups of lysine residues [97].  Using 
this approach, a quantitative isotopic and chemoenzymatic tagging (QUIC-tag) method was 
developed for O-GlcNAc analysis. In this method, O-GlcNAcylated peptides are first 
enriched by the modified chemoenzymatic enrichment method, discussed above, and then the 
biotin labeled O-GlcNAcylated peptides are dimethylly isotopically labeled.  By using the 
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QUIC-tag approach, many quantitative O-GlcNAc changes on proteins after inhibition of O-
GlcNAcase, as well as after different stimulations of the brain were identified [98].  
 
β-ELIMINATION MICHAEL ADDITION WITH DENTISTY TAGGED DITHIOTHRITOL 
(DTT)  
     Using chemoenzymatic enrichment (as above) combined with BEMAD, but using 
deuterated DTT (DTT-3D6) for one sample and light DTT for the other samples, allows for 
direct comparison of O-GlcNAc site occupancy, as long as the necessary controls are 
performed. For example, this approach was used with good results to compare O-GlcNAc 
site occupancy between sites on proteins from erythrocytes obtained from either normal of 
normal and diabetic patients [72].  The advantage of this approach is that it can be performed 
on inexpensive ion trap mass spectrometers using CID/CAD tandem mass spectrometry. The 
disadvantage (as discussed above) is that detection of O-GlcNAc is indirect. 
     With the development of these new methods, the pace of identification and site 
mapping of O-GlcNAcylated proteins is rapidly increasing. In fact, the total O-GlcNAc sites 
mapped within the past two years exceeds that known during the past twenty-years [1]. 
Figure 2 summarizes the current approaches available for identification and site-mapping O-
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Figure 2. O-GlcNAc enrichment and site mapping methods. O-GlcNAc sites can be 
mapped by: A) directly analyzing the purified target protein, cell extracts, fractionated 
lysates, or samples enriched for O-GlcNAc by immune affinity chromatography by ETD MS. 
B) Enriching for O-GlcNAc modified peptides, derived from the purified target protein, total 
cell lysates or fractionated lysates, by the PC-biotin method and subsequently analyzing by 
ETD MS. C) Modifying O-GlcNAc sites of enriched O-GlcNAc modified peptides using 
BEMAD and analyzing by CAD/CID MS. D) In culture labeling the proteins with GlcNAz 
and processing through PC-biotin or biotin enrichment methods. Various quantitative peptide 
tags may be introduced at specified steps to allow for comparative analysis of multiple sets of 
samples.  
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EXTENSIVE CROSSTALK EXISTS BETWEEN PHOSPHORYLATION AND O-
GLCNACYLATION 
 
     O-GlcNAcylation occurs on Ser(Thr) side chains of proteins at sites that may also 
be phosphorylated. Thus far, virtually every O-GlcNAcylated protein can also be 
phosphorylated [99]. After several O-GlcNAc sites were mapped and discovered to also be 
phosphorylation sites a “Yin-Yang” model was proposed for the relationship between O-
GlcNAcylation and phosphorylation [100]. This model suggested that O-GlcNAcylation is 
reciprocal to phosphorylation with mutually exclusive occupancy at the same site on a 
polypeptide. While largely correct for many proteins, the Yin-Yang model is an over-
simplification. Now that hundreds of O-GlcNAc sites have been mapped, and some cellular 
stimuli increase both modifications, it is clear that the interplay between O-GlcNAcylation 
and phosphorylation is both complex and very extensive.   
 
GLOBAL INTERACTIONS BETWEEN O-GLCNACYLATION AND PHOSPHORYLATION  
A competitive or reciprocal relationship between O-GlcNAcylation and 
phosphorylation has indeed been found in several global analyses. Global O-GlcNAc levels 
change after using various kinase activators and inhibitors. For example, activation of protein 
kinase A or protein kinase C decreased global O-GlcNAcylation and inhibitors of these 
kinases increased global O-GlcNAcylation [101]. Okadaic acid (OA), a broad spectrum 
phosphatase inhibitor has been used to explore the global interplay between O-
GlcNAcylation and phosphorylation. Indeed, in some cells, OA short-term treatment 
decreases O-GlcNAcylation [102]. However, since OA also induces a stress response that 
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increases O-GlcNAcylation of many proteins, these types of global treatments are not very 
informative. 
In hippocampal neuronal synapses, pharmacological elevation of O-GlcNAc in vivo, 
concomitantly increases phosphorylation of Synapsin I/II at serine9(PKA site), 
serine62/67(Erk1/2 site), serine603(CaMK II site)[103]. These and other studies indicate that the 
nature and direction of the crosstalk between these two post-translational modifications 
depends upon not only the protein but also the specific modification site.  
Chemoenzymatic enrichment methods and advances in mass spectrometry have 
allowed global comparisons of O-GlcNAcylation and phosphorylation at the individual site 
level. In studies to determine the affects of inhibiting glycogen synthase kinase 3 (GSK3) on 
O-GlcNAcylation, of the forty-five identified O-GlcNAcylated proteins, at least ten proteins 
(mostly cytoskeletal proteins) had increased O-GlcNAcylation, while nineteen other proteins 
(mostly RNA binding proteins) had decreased O-GlcNAcylation [66].  A recent study 
examined the affects of globally increasing O-GlcNAcylation, by inhibiting O-GlcNAcase, 
on the quantitative site occupancy of phosphate at over seven hundred phosphorylation sites 
in non-stimulated NIH3T3 cells increased O-GlcNAcylation quantitative site occupancy at 
over seven hundred phosphorylation sites [104]. Forty-eight percent of the phospho-sites 
were not actively cycling in these non-stimulated cells, as judged by insensitivity to okadaic 
acid (OA). However, of the remaining actively cycling phospho-sites nearly all had their 
level of phosphorylation affected by altered O-GlcNAcylation. Elevated O-GlcNAcylation 
significantly reduced phosphorylation at about two hundred and eighty sites and significantly 
increased phosphorylation at one hundred and forty-nine sites. These studies revealed the 
surprisingly extensive level of crosstalk between these two most abundant post-translational 
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modifications. This extensive crosstalk not only results from steric competition at the same or 
proximal attachment sites, but also it is now clear that phosphorylation regulates both OGT 
and OGA, and O-GlcNAc is being found to regulate an increasing number of kinases 
[64,105].  
Overexpression of OGT causes defective cytokinesis increasing polyploidy in cells, a 
feature common to many cancer cells [106].  In order to understand the molecular basis for 
OGT’s induction of defective cell division, a glyco-, phospho-SILAC proteomic analysis, 
using chemoenzymatic enrichment with PC-biotin and a combination of CID and ETD mass 
spectrometry was carried out on spindle/midbody preparations isolated from HeLa cells 
overexpressing either GFP (control) or OGT (experimental) [91].  A comparable number of 
phosphorylation and O-GlcNAcylation sites were mapped (three hundred and fifty  
phosphorylation sites on one hundred and ninety proteins vs one hundred and forty-one O-
GlcNAcylated peptides on sixty-four proteins). Seventeen percent of the phosphosites 
showed more than a fifty-percent decrease upon a two-fold overexpression of OGT and the 
resulting increase in global O-GlcNAcylation. Some (seven percent) phosphorylation sites 
had a more than two-hundred percent increase in site occupancy. These changes resulted in 
pronounced inhibition of the cyclin dependent kinase I (CDK 1) signaling pathway, and 
alterations in polo kinase and aurora kinase signaling, partially explaining the cytokinesis 
defects induced by OGT over-expression. These data clearly exemplify the importance of the 
interplay between O-GlcNAcylation and phosphorylation in cellular signaling pathways. 
Hyperphosphorylation of the microtubule bundling protein, tau is a characteristic of 
of Alzheimer’s disease (AD). It has also been known for sometime that tau is heavily O-
GlcNAcylated in normal brain [107]. These findings led to the proposal that defective 
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glucose metabolism in the brain results in lower O-GlcNAcylation of brain proteins, 
including tau, leading to abnormally increased hyperphosphorylation associated with AD 
[108].When tau becomes hyperphosphorylated, it forms visible tangles within neurons and is 
referred to as paired helical filamentous tau (PHF-tau). To date, more than thirty 
phosphorylation sites have been mapped on PHF-tau, and many of them have been used to 
produce site-specific phosphorylation antibodies [109].  While there are more than twelve 
putative O-GlcNAc sites on tau, only a few sites have been mapped and no site specific 
antibodies have been made [107]. Increased O-GlcNAcylation negatively regulates tau 
phosphorylation at multiple sites, and hyperphosphorylated tau has decreased O-
GlcNAcylation. Several studies have shown that decreased flux through the HBP or 
decreased expression of OGT result in tau hyperphosphorylation in animal models [110,111]. 
The potent OGA inhibitor, Thiamet G (TMG), increases global O-GlcNAcylation effectively 
in whole animals and crosses the blood-brain barrier [112]. TMG treatment increased O-
GlcNAcylation and decreased phosphorylation at pathologically relevant sites on tau, Thr231 
and Ser396 in PC12 cells and Ser422 in rat cortex and hippocampus [112].  
     Endothelial nitric oxide synthase (eNOS) is regulated by reciprocal O-
GlcNAcylation/phosphorylation.  Ser1177 phosphorylation of eNOS by AKT kinase activates 
the enzyme and is important in positively regulating penile erection, and phosphorylation on 
Thr495 of eNOS acts as a negative regulator.  Ser615 and Ser633 phosphorylation can also 
acivate eNOS. In diabetic rats excessive O-GlcNAcylation at Ser1177 prevents AKT activation 
of eNOS without affecting phosphorylation at Thr495, Ser615 and Ser633 [113], and in humans 
with diabetes O-GlcNAcylation of eNOS contributes to erectile dysfunction [113].  
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     Upon activation of the insulin signaling cascade, phosphorylation of AKT at 
Thr308 is increased. Concomitantly, phosphorylations on IRS-1 at Ser307 and Ser632/635  are 
decreased. When OGT is over-expressed in mouse liver, increased O-GlcNAcylation of both 
AKT and IRS-1 occurs, but results in decreased phosphorylation at Thr308 of AKT and 
increased phosphorylation at Ser307 and Serine632/635 on IRS1. These findings support the 
hypothesis that the crosstalk between O-GlcNAcylation and phosphorylatioin is complex and 
is not simply a ‘yin-yang’ relationship. The two modifications work synergistically to 
regulate insulin signaling [114].  
     The cycling dynamics of O-GlcNAcylation and phosphorylation are also 
differentially regulated. For example, on the transcription factor, Sp1, O-GlcNAcylation of 
Sp1 peaks at thirty minutes post insulin stimulation, followed by a steady decline, and 
reaches low levels by four hours. In contrast, the insulin stimulated phosphorylation on Sp1 
increases gradually and reaching a peak around four hours after insulin treatment [115] [116].  
     Despite many exceptions, there are numerous proteins, such as c-Myc, estrogen 
receptor β (ER-β) and Akt [105], in which the O-GlcNAc moiety and the phosphate residue 
compete for the same hydroxyl group, as proposed in the ‘yin-yang’ model. One of the best-
studied examples is the c-Myc oncogene protein. The protooncogene, c-myc, regulates 
transcription of genes involved in cell proliferation, apoptosis and metabolism [117]. The 
major O-GlcNAcylation site on c-Myc was mapped to Thr58, which is also a GSK3β 
phosphorylation site within the transaction domain [60].  Frequent mutation of this site is 
found in human lymphomas, demonstrating the importance of this site in tumor progression 
[117]. Antibodies specifically detecting O-GlcNAcylated Thr58, phosphorylated Thr58, as 
well as Thr58-unmodified c-Myc were used to study the respective roles of each modification. 
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Serum starvation stops cell growth and greatly increased Thr58 O-GlcNAcylation. In contrast, 
when cells were stimulated to grow by serum addition, O-GlcNAcylation at Thr58 very 
rapidly disappears and is replaced by increased Thr58 phosphorylation by GSK3b. The 
proximal site, Ser62, is a priming phosphorylation site and a substrate for mitogen activated 
protein kinases. Phosphorylation at Ser62 is necessary for Thr58 phosphorylation by GSK3β. 
When Ser62 is mutated to alanine, not only does Thr58 no longer become phosphorylated, but 
also the extent of O-GlcNAcylation at Thr58 increases dramatically. Lithium chloride, a 
GSK3β inhibitor, also increased O-GlcNAcylation at Thr58 similar to the  Ser62Ala mutation 
[118].  Estrogen receptor b (ER-β) is reciprocally O-GlcNAcylated/phosphorylated at Ser16 
[55,119].  Ser16 is within a region of ER-b with high Pro, Glu, Ser and Thr (PEST) score, 
which is related to rapid protein degradation. Site-directed mutagenesis comparisons between 
wild type ER-b to mutants, S16A, S16E suggested that the O-GlcNAcylated ER-b was much 
more stable, but less transcriptionally active, while the phosphorylated ER-b was 
transcriptionally more active, but rapidly degraded [120]. Consistent with the biological 
studies, NMR analysis and molecular dynamics simulation of synthesized peptides, 
suggested that phosphorylation in Ser16 discourages b-turn formation at the N-terminus of the 
protein, resulting in a more extended structure, while Ser16 O-GlcNAcylated peptides 
promoted b-turn formation, adopting a more stable structure, which to some degree might 
explain why O-GlcNAcylation on Ser16 can stabilize the protein [121].  A similar dynamic 
interplay between O-GlcNAcylation and phosphorylation occurs on the C-terminal domain 
(CTD) of RNAP II. The CTD of RNAP II is extensively phosphorylated during the transition 
from the preinitation complex to the assembly of the elongation complex during 
transcription. On a subset of the RNAPII, the CTD contains no phosphate, but is extensively 
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O-GlcNAcylated [122]. The mutually exclusivity of the two modifications on CTD was 
shown in vitro. OGT was completely unable to O-GlcNAcylated a CTD substrate that 
contained even a single phosphate moiety. Likewise, the CTD kinase was unable to 
phosphorylate a CTD containing only a single O-GlcNAc, despite many other sites being 
available [123].  Another example of direct reciprocity is that of Iκ kinase β (IKKβ). IKKb is 
O-GlcNAcylated at Ser733 in its C-terminus, which is also an inactivating phosphorylation 
site. The reciprocal interaction in this site is responsible for regulating IKKβ catalytic activity 
[124].  
     Perhaps more common than direct site competition is the interplay that occurs 
between O-GlcNAcylation and phosphorylation at proximal sites. It should be noted that the 
Stoke’s radius of an O-GlcNAc is several times larger than that of a phosphate moiety, 
despite the lack of a charge on the sugar (Figure 3).  The important tumor suppressor, p53, 
bears proximal O-GlcNAc (Ser149) and phosphate (Thr155) residues. O-GlcNAcylation of 
Ser149 reduces phosphorylation at Thr155, which subsequently blocks the interaction between 
Mdm2, an E3 ubiquitin lyase, and p53, a prerequisite for proteasomal degradation of p53. 
Thus, increased O-GlcNAcylation of p53 at Ser149 results in decreased p53 ubiquitination and 
stabilizes the protein p53 [125]. Mutation of the Ser149 O-GlcNAc site on p53 to alanine 
increases phosphorylation at Thr155. Three dimensional structural analysis shows that these 
two sites are located on a flexible loop with close proximity of only 11.58 Å, suggesting that 
there might not be enough space for dual occupancy of both phosphate and O-GlcNAc 
groups at these two sites. 
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Figure 3. O-GlcNAc vs. O-phosphate modification of CaMKIV. The structure of 
CaMKIV was obtained through the automated comparative modeling program SWISS-
MODEL. Mouse CaMKIV sequence (PO8414) was analysed by the automated mode. The X-
ray crystal structure of Human CaMKIV (PDB code 2w4oA) was chosen as a closet match 
template to create a model of CaMKIV. The PDB created through the homology-based 
modeling was then analysed using MacPymol to create the figure presented above. A) 
Unmodified CaMKIV model, the protein is depicted to show the secondary structure (grey) 
with Ser 189 (green) and Thr200 (red) represented in stick model. The boxed area was 
enlarged to show the modified forms. B) O-GlcNAcylated CaMKIV model with O-GlcNAc 
(carbon is yellow, hydrogen is white, nitrogen is blue, oxygen is pink, sphere model) attached 
to Ser189. C) O-phosphate CaMKIV model with phosphate (phosphate is orange, others as in 
B.) attached to Thr200.  D) Space filling model of a GlcNAc residue E) Space filling model 
of a phosphate residue.  
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Site mapping studies have recently revealed a similar proximal interplay between O-
GlcNAcylation and phosphorylation on CaMKIV, a key kinase regulating gene expression in 
neurons and other cells. CaMKIV is predominantly expressed in brain, T-lymphocytes and in 
the testis. It is a multifunctional Ca2+/calmodulin dependent Ser/Thr kinase, that regulates 
downstream protein activities according to changes in intracellular Ca2+ concentrations. 
CaMKIV is O-GlcNAcylated and phosphorylated on several sites. Five O-GlcNAcylation 
sites were mapped on CaMKIV and O-GlcNAc on Ser189, Thr57/Ser58 were evaluated for 
their interactions with phosphorylation, mainly at the key regulatory phosphorylation site at 
Thr200. Phosphorylation at Thr200, which is the target of CaMK kinase (CaMKK), increases 
CaMKIV kinase enzymatic activity. Upon neuronal depolarization using ionomycin to 
increase intracellular Ca2+, phosphorylation at Thr200 rapidly increases peaking at two 
minutes, and decreasing after five minutes. In contrast, O-GlcNAcylation at Ser189 
reciprocally decreased at 2 min, and returned to basal level at around 10min. Mutating 
Ser189 to alanine dramatically increases both the phosphorylation of CAMKIV at Thr200 
and its constitutive enzymatic activity. Mutation of Thr57/Thr58 to alanine inactivates the 
kinase.  Analysis of the three-dimensional structure of CAMKIV revealed that all three of 
these O-GlcNAc sites are located within the catalytic cleft, near the ATP binding residues 
Lys75 and Asp185 [64].  
As discussed above, O-GlcNAcylation and phosphorylation certainly have extensive 
crosstalk due to steric competition of the modifications themselves at the same or proximal 
sites on proteins. However, they also influence each other by each modification regulating 
the activities or localizations of the other’s cycling enzymes. For example, OGT is directly 
activated by tyrosine phosphorylation and is itself O-GlcNAcylated [15], and CAMKIV is 
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directly inhibited by O-GlcNAcylation [64]. Src, a well known tyrosine kinase important to 
cancer, phosphorylates OGT in vitro [126].  Upon insulin stimulation, OGT is recruited to 
the plasma membrane by binding phosphatidylinositol 3,4,5-triphosphate (PIP3).  Insulin 
receptor tyrosine phosphorylates OGT, increasing its activity [114,126].  OGT also forms a 
stable and active complex with Ser/Thr protein phosphatase PP1β and PP1γ in rat brain 
[127].  Additionally, PP1 and the mitotic kinase Aurora B form a complex with OGT and 
OGA during M phase of the cell cycle. The Aurora B kinase inhibitor, ZM447439 (ZM), 
disrupts Aurora B’s localization to the mid-body during cytokinesis, as well as its staining 
co-localization with OGT.  The transient complex that forms at the midbody during 
cytokinesis regulates both the phosphorylation and O-GlcNAcylation of many proteins that 
regulate cell division, including vimentin [6].  
     In summary, phosphorylation and O-GlcNAcylation can reciprocally or synergistically 
interact with each other on the same sites or proximal sites within proteins (Figure 4). This 
interplay serves to fine tune signaling, transcription and other cellular processes in response 
to nutrients and stress. This dynamic interplay is further complicated by the regulation of 
OGT and OGA by phosphorylation and the increasing numbers of kinases that appear to be 
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Figure 4. Interplay between O-GlcNAcylation and phosphorylation. A) Single site 
reciprocal interplay B) Proximal sites reciprocal interplay C) Spatially proximal sites with 
reciprocal interplay D) Distant sites with varied interplay 
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HOW DOES A SINGLE CATALYTIC PEPTIDE (OGT) SPECIFICALLY 
MODIFY MORE THAN A THOUSAND DIFFERENT PROTEINS? 
 
     As mentioned above, there are three hundred and eighty-five known Ser/Thr 
kinases in humans, each kinase functions in its own specific substrates and has its own 
regulation signal[128]. However, in mammals there is only one known gene for OGT and 
only two known in plants. Thus, the site specificity of phosphorylation and O-GlcNAcylation 
are determined by very different mechanisms.  How does this single protein specifically 
modify so many different sequences within proteins? There is precedence for this problem in 
biology. For example, there is only a single gene encoding RNAP II’s catalytic subunit. How 
then does RNAP II specifically transcribe in a regulated way from so many different 
promoters? It is well documented that RNAP II’s activity is determined by its forming many 
transient protein complexes that form holoenzymes with precise specificity. Current data, 
suggests that this mechanism is how OGT’s specificity is also determined. That is, in a living 
cell many different holoenzymes, that are comprised of OGT and other polypeptides, form 
under specific conditions and the many resulting OGT complexes serve to specifically target 
the catalytic subunit to its target proteins (Figure 5). In addition, OGT also has specific 
sequence requirements, but not an absolute consensus sequence.    
     Early work showed that adapter or targeting proteins for OGT bind to its TPR-
repeats to target the enzyme to transcription complexes and other targets [129-131]. Many 
transcription factors, such as Sp1, c-myc, are O-GlcNAcylated [60,132]. O-GlcNAcylation of  
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Figure 5. OGT targeting to specific proteins by adaptor/targeting proteins. A) In the 
basal state OGT does not interact with an adaptor or target protein. B) Upon stimulation 
(such as nutrient, stress and hormone) OGT interacts with adaptor/targeting proteins. C) The 
adaptor/targeting protein recruits OGT to its target protein specifically increasing its rate of 
O-GlcNAcylation in signal dependent manner.  
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Sp1 inhibits its binding ability with other Sp1 proteins as well as TATA-binding 
protein-associated factor II 110 (TAFII110) through breaking the hydrophobic interactions 
between theses proteins [132,133]. Homomultimerization of Sp1 is required to induce 
transcription activation, and Interaction with TAFII110, is needed for binding with general 
transcription factor II D, and conducting DNA polymerase II dependent transcription [134].  
The role of OGT in transcription repression was later clarified. By tethering OGT to 
the Gal4 DNA binding domain, it was shown recruitment of OGT to gene promoters 
enhanced the inhibitory effect in both basal and Sp1-activated transcription level. Later 
analysis showed OGT could be recruited to promoters by another transcription repressor, 
mSin3A, where histone deacetylases 1(HDACs) interacted with the complex, resulting in 
transcription repression. Truncation experiments indicated that the first 6 TPRs of OGT, 
which mediates protein-protein interaction, are the main motif interacting with the putative 
paired amphipathic helix (PAH) domains of mSin3A [9,129].    
      Through yeast two hybrid screenings, more and more adaptor proteins for OGT 
have been identified. And they were initially termed as OGT interacting protein (OIP).  
Firstly, two highly homologous proteins were isolated, GABAA receptor-associated protein 
(GRIF-1) and OIP106 (now it is known as Trak1). The interaction between OGT and either 
of these two proteins were confirmed both in vivo and in vitro. Consistent with previous 
results, it’s the first 6 TPR domain of OGT that interact with these two adaptor proteins 
[131]. Confocal and electron microscopy data showed OIP106 colocalized with RNAP II, 
and the complex of OIP106, RNAP II and OGT was detected in Hela nuclear extracts. This 
raised the possibility that OIP106 and GRIF-1 may serve as targeting OGT to RNAP II and 
GABAA separately [130].  
	   38	  
A following up large-scale yeast two-hybrid screen performed using human fetal 
brain cDNA library, identified 27 putative OGT binding proteins. These proteins belong to a 
wide range of functional classes, such as cytoskeletal proteins, transcription factors and 
proteins involved in development, metabolism. Of these 27 proteins, myosin phosphatase 
targeting subunit 1 (MYPT1), a known targeting regulatory subunit of PP1β, and coactivator-
associated argininemethyltransferase 1 (CARM1) were confirmed to interact with OGT 
directly and affect OGT substrate specificity in vitro. The MYPT1 or CARM1 interacting 
proteins were enriched through recombinant protein conjugated column, and then sent for in 
vitro OGT labeling. When recombinant MYPT1 or CARM1 was added in the reaction 
system, OGT activity towards those MYPT1, CARM1 interacting proteins is increased. 
Interestingly, the O-GlcNAc of MYPT1 and OGT are also enhanced, suggesting that the 
adaptor proteins for  O-GlcNAcylating MYPT1 are also within the enriched protein pool. In 
vivo knock down of MYPT1 by RNAi decreased O-GlcNAcylation of many proteins even 
though the activity of OGT and OGA were not changed. This experiment confirmed the 
existence of interaction between OGT and adaptor proteins.  Changing the level of these 
adaptor proteins can alter OGT substrate specificity in vitro and global O-GlcNAcylation 
spectrum in vivo provided more evidence to support our hypothesis: OGT regulates its 
substrate specificity through forming holoenzyme with different adaptor proteins. Several 
other adaptor proteins have also been reported in recent years.  Ataxin-10 interacts with OGT 
p110 in brain tissue, and this interaction was competed by the mitochondrial OGT form, 
OGT p78. In vitro OGT assay using PC12 cell extract shows Atx-10 can increase OGT 
activity by 2-fold [135].  
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This adaptor theory was also confirmed in the O-GlcNAcyaltion of several specific 
proteins [13,14]. For example, when Neuro-2a cells were derpived of glucose, OGT interacts 
with p38. Through a large-scale co-immunoprecipitation, NF-H was identified as a substrate 
for both p38 and OGT, thus a possible targeting protein candidate for OGT with adaptor 
protein p38 interaction. This was confirmed by pharmacologically inhibiting p38 activity, 
which abolished O-GlcNAcylation of NF-H induced by glucose deprivation even though the 
interaction of OGT with NF-H was not changed [13]. 
Another OGT-adaptor protein-substrate example comes from transcription factor 
FoxO and PGC-1α. The interaction among these three proteins was confirmed cultured rat 
hepatoma Fao cells. In vitro OGT assay showed PGC-1α increased OGT activity towards 
FoxO through increasing the interaction between OGT and FoxO. Glucose stimulation has 
been shown to enhance O-GlcNAcylation of FoxO and its transcriptional activity in Fao cell 
[89]. This increase of O-GlcNAcylation was also PGC-1α dependent.  
       These two examples showed not only the existence of OGT-adaptor proteins-
target proteins interaction, but also how this interaction varies to extracellular changes, such 





O-GlcNAcylation has been recognized playing an essential role in regulating many 
cellular processes, such as transcription, cell signaling, metabolism and protein stability 
(more for reviews [7,136]). Thus it’s not surprising that O-GlcNAcylation is involved in 
various diseases, like cancer, diabetes as well as neurodegenerative disease and 
cardiovascular related protection (more for reviews [137,138]).  
The development of various rapid, high efficient technologies for O-GlcNAc site 
mapping, enables us access many new truths about this common posttranslational 
modification, as well as improve current theory about the interaction between O-
GlcNAcylation and phosphorylation. In the future, better understandings of how O-
GlcNAcylation acts in regulating cell function, suvival and disease progression are available 
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Diabetes is an emerging global epidemic, of which, type II diabetes accounts for more 
than 90% of the cases. Development of insulin resistance, which shows dampened cellular 
response to insulin, heralds the onset of type II diabetes. Previous studies have identified 
many components involved in the insulin signaling cascade and revealed extensive regulation 
of insulin signaling by phosphorylation. Insulin Receptor Substrate 1(IRS1) is one of the 
most critical components in insulin signaling, whose phosphorylation is also key to 
regulating the insulin signaling pathway.  O-GlcNAcylation, as phosphorylation, also occurs 
on Serine and Threonine residues, where it serves as a nutrient sensor and it often 
dynamically competes with phosphorylation. Recently O-GlcNAc modification has been 
detected on IRS1. My thesis project was to decipher the roles of O-GlcNAcylation in insulin 
resistance as well as to determine how O-GlcNAcylation on IRS1 regulates the insulin 
signaling cascade.  
We first studied insulin signaling activity downstream of IRS1 in mouse adipocyte 
3T3-L1 cells. We observed different insulin signaling activations under low and high cellular 
O-GlcNAcylation conditions. With low O-GlcNAcylation levels, when O-GlcNAc 
transferase is inhibited by AcSG treatment, insulin stimulation of IRS1/PI3K/AKT pathway 
was elevated, which is responsible for the metabolic actions of insulin, such as glucose 
uptake and gluconeogenesis.  In contrast, when OGA is inhibited by Thiamet-G (TMG), 
resulting in  high O-GlcNAcylation levels, the IRS1/RAS/ERK pathway controlling cell 
growth and differentiation is further activated by insulin. These observations indicated a role 
for O-GlcNAcylation in regulating the flux down divergent insulin signaling pathways 
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downstream of IRS1, and highlighted the importance of O-GlcNAcylation of IRS1. As we 
are interested in O-GlcNAcylation’s role in insulin resistance, we later focused on the 
metabolic insulin signaling pathway, and confirmed that AcSG treatment not only boosted 
insulin stimulated glucose uptake, but it also enhanced the  IRS1/PI3K/AKT signaling 
cascade. Inhibition of OGT  also reversed insulin resistance caused by Tumor necrosis factor 
alpha (TNFα) pre-treatment. The laboratory is continuing to compare the overall 
phosphorylation changes on signaling molecules among high, normal and low O-
GlcNAcylation levels.  
Besides the overall insulin signaling changes, we examined phosphorylation changes 
on the IRS1 protein under various O-GlcNAcylation conditions. We first identified the 
phosphorylation pattern of IRS1 by two-dimensional electrophoresis. Most dramatic changes 
were observed on IRS1 under low O-GlcNAcylation condition, with IRS1 remaining in two 
isolated patterns: an increase in highly phosphorylated IRS1 and but also the presence of 
poorly  phosphorylated IRS1. We further measured phosphorylation levels of IRS1 by 
phospho-specific antibody, which showed increased serine phosphorylation and decreased 
tyrosine phosphorylation on IRS1 with low cellular O-GlcNAcylation.  
I also explored the site-specific function of O-GlcNAcylation on IRS1. Previous 
literature showed overexpressed IRS1 in a mammalian cell line is O-GlcNAcylated, we 
further showed O-GlcNAcylation also existed on endogenous IRS1. We consistently found 
elevated O-GlcNAcylated IRS1 in both type I and type II diabetes rat models, which 
indicated that O-GlcNAcylation of  IRS1 was highly associated with diabetes progression. In 
order to clarify site-specific mechanisms of O-GlcNAcylation of IRS1 in type II diabetes, we 
mapped O-GlcNAcylation sites on IRS1 through combination of CAD-MS/MS and ETD-
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MS/MS. Due to technology limitation, even though we know more sites exist, we only 
identified two novel O-GlcNAcylation sites, Ser635 and Ser1005 on mouse IRS1 protein, 
increasing the number of known O-GlcNAc sites on IRS1 to 8. Ser1005 O-GlcNAcylation on 
human and rat IRS1 have been shown to be involved in regulating PI3K recruitment to IRS1, 
and thus inactivating insulin signaling pathway.  Through site-mutagenesis and protein 
engineering, we found O-GlcNAcylation of Ser635 inhibited overall O-GlcNAcylation on 
IRS1 by blocking its addition at other sites on the protein. Further study clarified a negative 
O-GlcNAcylation feedback existed between Ser635 and the C-terminal loci of IRS1 
(including Ser1005 and other unmapped sites), thus the overall effect of O-GlcNAcylation on 
Ser635 is to inhibit addition of O-GlcNAc on the C-terminus of IRS1, which results in 






Obesity/diabetes is a rising epidemic in the world. In which, type II diabetes accounts 
for 90-95% of all the diagnosed cases of diabetes. The vast majority type II diabetic patients 
are insulin resistant, which results in dampened signaling activation under insulin stimulation 
[1]. Under insulin stimulation, both Ras-ERK and PI3K-Akt signaling can be activated. 
These two signaling pathways might also intersect to regulate each other and co-regulate 
downstream functions [2]. Once insulin binds with the two extracellular α-subunits of insulin 
receptor, the two intracellular β-subunits transphosphorylate one another, further increase the 
tyrosine kinase activity. The insulin receptor tyrosine kinase continues to phosphorylate the 
downstream molecules. IRS and Shc are two of more than ten substrates identified in the 
insulin signaing cascades. 
Phosphorylated tyrosines on IRS act as docking sites for PI3K, which in turn becomes 
activated. The activated PI3K contains two subunits: p110 calalytic subunit and p85 catalytic 
subunit. PI3K stimulates production of PI3-phosphate, which activates Akt through 
activating PDK1 and bringing Akt close to the PDK1. Akt has numerous and diverse targets, 
such as GSK3, FOXO-1 etc. Phosphorylation of these targets result in increased glucose 
uptake and glycogen synthesis as well as decreased gluconeogenesis.  
Another major pathway for insulin signaling is the MAP kinase pathway. Insulin 
activates IRS, Gab1 and Shc, allowing them to recruit Grb2. Grb2 can bring SOS to the 
plasma membrane, where it activates G protein signaling cascade: Ras-Raf-MEK-ERK. 
Different from PI3K/AKT pathway, this G protein signaling is more associated with cell 
proliferation and differentiation effect of insulin [3].  
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O-GlcNAcylation is directly involved in diabetes and insulin resistance [4]. 
Overexpression of OGT in muscle, fat and liver leads to insulin resistance and 
hyperleptinemia [5].  Recent research described a novel phosphoinositide-binding domain in 
OGT. Under insulin stimulation, OGT translocates from nucleus to the plasma membrane, 
and specifically binds with PIP3. When OGT resides at the cell membrane, a cascade of 
phosphorylation signaling is regulated and O-GlcNAc attenuates insulin signaling [6]. 
Additionally, many key insulin signaling proteins, such as IRS, PDK, AKT, GSK3b, are 
substrates of OGT [7]. Meanwhile, there remains much to be learned about the specific roles 
of O-GlcNAcylation in insulin resistance.  6-Acetamido-6-deoxy castanospermine (6-Ac-
Cas), another potent and cell permeable inhibitor of OGA was shown to be unable induce 
insulin resistance in 3T3-L1 adipocytes [8]. Both OGA overexpression and OGT knockdown 
in 3T3-L1 cells failed to prevent or mitigate glucose/insulin-induced insulin resistance [9].  
IRS1 and IRS2 are key targets of insulin receptor tyrosine kinase.  As an upstream 
adaptor protein in insulin signaling, a Yin-Yang, site-dependent phosphorylation regulation 
mechanism has been revealed on IRS. Once tyrosine residues are phosphorylated, and act as 
binding sites for SH2 domain-containing proteins, IRS positively mediates the PI3K branch 
of insulin signaling, which is critical for the regulation of insulin’s metabolic effects. On the 
other side, IRS also contains many Serine/Threonine residues, which are heavily 
phosphorylated even in basal conditions. Serine phosphorylation of IRS is associated with 
dampened insulin action and underlies one molecular mechanism of insulin resistance [10].   
Besides heavy phosphorylation on IRS, it is also O-GlcNAcylated.  The O-
GlcNAcylation sites are mapped to be mostly located in the C-terminus and close to docking 
sites of SH2 domain-containing proteins. The inhibition of PI3K binding with IRS1 due to 
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the C-terminal O-GlcNAcylation represents an additional layer of Yin-Yang regulation of 
IRS1 as well as insulin action [11].   
O-GlcNAcylation and phosphorylation regulate insulin signaling simultaneously. 
However, how these two PTMs are interacting with each other is still under investigation. 
The present study was conducted to further investigate how O-GlcNAcylation and 
phosphorylation are crosstalking with each other in insulin signaling as well as to determine 
how O-GlcNAcylation of IRS1 regulates insulin action. We found that upon insulin 
stimulation, simply increasing or decreasing O-GlcNAcylation levels in 3T3-L1 adipocytes 
activates different alternative downstream signaling pathways. The different activated 
signaling pathways thus result in different insulin actions. We also mapped two new O-
GlcNAcylation sites on mouse IRS1, Ser 635 and Ser 1005. O-GlcNAcylation on  Ser635 
negatively regulates O-GlcNAcylation at the  C-terminus of IRS1, and thus positively 




Reagents – All chemical reagents were obtained commercially unless otherwise noted. 
Ac4SGlcNAc was synthesized in laboratory via published protocol [12]. Recombinant insulin 
was purchased from Sigma and TNFα was from Invitrogen. Antigen purified CTD 110.6 
acites were purchased from antibody facility at University of Alabama, Birmingham, and 
then purified through a GlcNAc-Agarose column. Antibodies used in this project were 
against IRS1 (Millipore), myc (Santa Cruz), PI3K p85, phosphoThr308AKT, 
phosphoSer473AKT, AKT, phosphoThr202/Tyr204-ERK1/2, ERK1/2, phosphoSer21/9-
GSK3ab, GSK3ab (Cell Signaling), actin (Sigma). Horseradish peroxidase-conjugated 
secondary antibodies (anti-mouse IgG, anti-rabbit IgG, anti-mouse IgM) were from Sigma. 
Blots were developed with ECL reagent (Denville Scientific) and Hyper-film (GE-
Amersham Biosciences).  
 
Cell Culture – 3T3-L1 preadipocytes were grown and differentiated into adipocytes 
as described [13] with slight modifications. The 3T3-L1 preadipocytes (within passage 3-10) 
were cultured in DMEM (4.5 g/L or 25mM glucose, Invitrogen) with 10% FBS (Invitrogen), 
100 units/ml penicillin and 100 µg/ml streptomycin (Corning). Cells were kept at 37°C 
incubator with 5% CO2 until reaching confluence (Day -2).  48 h later (Day 0), DEME 
culture medium with FBS and P/S were changed with 0.33µM DEX, 0.5mM IBMX, 1µg/ml 
insulin and 2µM rosiglitazone (Cayman Chemical) added freshly. The cells were kept in the 
differentiation medium for another 3 days (Day 3). After this, cells were incubated in DMEM 
culture medium containing FBS, P/S with1µg/ml freshly added insulin for 2 days (Day 5).  
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The medium was changed every 2 days afterwards. The differentiated 3T3-L1 cells were 
used for experiments within Day 9 ~ Day 11.  For undifferentiated 3T3-L1 cells, very diluted 
status was maintained to avoid cell-cell contact.  
CHO/IR and CHO/IR/IRS1 were kindly provided by Dr. Morris White laboratory 
(Harvard University), and the cells were grown with F-12 media supplemented with 10% 
FBS and 1xP/S. 293T cells were grown in DMEM media with 10% FBS and 1xP/S.  
 
OGT and OGA inhibition on 3T3-L1 – 3T3-L1 cells seeded on 24-well plate were 
differentiated in DMEM containing 25mM glucose and 10% FBS, 1x P/S. At Day 9 the 
differentiated 3T3-L1 cells were incubated with 4 different culture media: 1) DMEM -5mM 
glucose 2) DMEM -5mM glucose with 0.6nM insulin 3) DMEM -25mM glucose 4) DMEM -
25mM glucose with 0.6nM insulin plus 1% FBS, 1x P/S for 18 hours. In each culture media, 
we had 4 different treatments to regulate cellular O-GlcNAcylation levels: 1) no treatment 2) 
1 µM TMG 3) 50 µM Ac-5SGlcNAc (AcSG) 4) 100 µM PUGNAc. So in total, we have 16 
different culture and treatment conditions for differentiated 3T3-L1 cells. They were then 
serum starved and insulin deprived for 2h with a similar media rather than no FBS. After 
washing with Krebs-Ringer-Bicarbonate-HEPES (KRBH, 25mM HEPES, pH 7.6, 120mM 
NaCl, 4.6mM KCl, 1.9mM CaCl2, 1mM MgSO4, 1.2mM KH2PO4) buffer, the cells were 
cultured in KRBH for 10 min and then stimulated with 100nM insulin for another 15 min. 




Animals – All animals were processed following animal safety protocol according to 
Johns Hopkins University School of Medicine. 2-3 weeks old male (250g) Sprague Dawley 
rats were purchased from Harlan Laboratories and divided into 2 groups. After acclimation, 
they were randomly assigned into normal diet (Control, n=3) and high fat diet group (HF, 
n=3). After fed for 12 weeks, the rats were harvested and the abdominal fat pad tissue were 
collected and prepared for IRS1 immunoprecipitation analysis.  
 
Plasmid constructs and protein overexpression – Constructs encoding myc-tagged 
mouse IRS1 as well as its control construct were kindly provided by Dr. Yehiel Zick 
laboratory (Weizmann Institute, Israel). Construct encoding recombinant full-length human 
OGT (ncOGT) was a gift from Dr. Suzanne Walker laboratory (Harvard University). For 
IRS1 overexpression, 293T cells, seeded at 1x 106 cells on 10-cm dishes the day before, were 
transfected using Lipofectamine 2000 according to the manufacturer’s instruction 
(Invitrogen). Fresh DEME media were changed 12 h later and the cells with overexpressed 
mouse IRS1 were harvested for the following experiments 48 hours later.  
For constructs with Ser635A and Ser635E site mutation, the following primer pairs 
were used: 1) Ser635A: 5’ G CCC ATG AGC CCC AAG GCT GTA TCT GCC CCA CAG 
CAG- 3’ and 5’- CTG CTG TGG GGC AGA TAC AGC CTT GGG GCT CAT GGG C-3’ 2) 
Ser635E: 5’- G CCC ATG AGC CCC AAG GAA GTA TCT GCC CCA CAG CAG 
-3’ and 5’- CTG CTG TGG GGC AGA TAC TTC CTT GGG GCT CAT GGG C-3’. PCR 
was conducted with using pfu Turbo (Agilent) with slightly modified procotol from 
QuickChange Lighting Site-Directed Mutagenesis (Stratagene). Briefly, 20 cycles of 95°C 30 
s-65°C 30 s-72°C 1min/kb PCR reaction were performed first, followed with 2 h DpnI 
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(NEB) incubation at 37°C to cut the wild type construct template. Cell transformation was 
done using XL-10 Gold competent cell with β-ME (Stratagene). Positive colonies were 
selected and sequenced by sequencing facility at Johns Hopkins University.  
For mIRS1 1-900 truncations, primer pair 5’-
GGAGAATATGTGAATATTGAATTCTAGAGCGGCCAGCCTGG-3’ and 5’- 
CCAGGCTGGCCGCTCTAGAATTCAATATTCACATATTCTCC-3’ was designed for 
PCR. Similar protocol was used compared with Ser635A/E site mutagenesis rather than 
using KOD DNA polymerase (Millipore).  
 
Western blotting and immunoprecipitation – Cells were washed with cold PBS for 3 
times and then harvested with NP-40 lysis buffer (1% NP-40, 20mM Tris-HCl, pH8.0, 
150mM NaCl, 1mM EDTA) plus various inhibitors (1µg/ml leupeptin, 2µg/ml antipain, 
10µg/ml benzamidine, 10U/ml aprotini, 1mM PMSF, 2.5mM sodium orthovanadate, 10mM 
sodium fluoride, 10mM β-glycerophsphoate, 1µM TMG and 10µM PUGNAc). The whole 
cell extract was either sonicated 3 x 10s with a 30s pause on ice or incubated on ice for 30 
min with vortexing every 10 min. The final cell lysate was collected through spinning the 
whole cell extract at 16,000 g for 20 min at 4°C. The lysate protein concentration was 
measured with Bio-Rad protein assay.  
For 3T3-L1 cells differentiated within 24-well plate, they were directly lysed with 
pre-warmed 6x SDS loading buffer (0.35M Tris-HCl, pH 6.8, 10.28% SDS (v/v), 36% 
glycerol, 0.012% bromophenol blue (w/v), 5% β-mercaptoethanol). With the whole cell layer 
extracted into the loading buffer, the whole cell extract were transferred into 1.5ml microtube 
and boiled at 100°C for 10 min to break DNA in nucleus.  
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As for immunoprecipitation, 1mg cell lysate was precleared with control IgG and 10 
µl pre-washed dynabeads® magnetic beads (Invitrogen) for 30 min at 4°C on rotator. 0.1% 
lysate were saved as input and the rest were incubated with targeting antibody overnight at 
4°C on rotator. Next day, 20 µl magnetic beads were added into the lysate-antibody mixture 
for another 1 h incubation. The magnetic beads were then washed with NP-40 lysis buffer for 
6 times with mild vortex each time. After wash, the beads were mixed with 6x SDS loading 
buffer, and boiled at 100°C for 5 min.  
Pre-cast Criterion SDS-PAGE gels (Bio-Rad) were used to resolve the proteins, 
which were transferred to nitrocellular membrane (Bio-Rad). The membrane was blocked 
with 3% BSA (w/v, Sigma) or 5% milk (Safeway) in 0.1% Tween-20 TBST, and 
immunoblotted with indicated primary antibodies overnight at 4°C. After 3 times of 10 min 
wash with TBST on the next day, the membrane was incubated with HRP conjugated 
secondary antibody for 2 hours at room temperature followed with 3 times 10 min TBST 
wash and signal detection by ECL reaction.  
 
Two-dimensional gel electrophoresis – One volume of 1mg CHO/IR and 
CHO/IR/IRS1 cell lysate were mixed with 4 volumn of 1:1 (v/v) 1mM HCl acidified acetone 
and methanol followed with overnight incubation at -20°C. The mixture was then spun at 
15,000g for 15 min at 4°C. After carefully removing all the solvents, the protein pellets were 
air dried to eliminate acetone and methanol. 200 µl rehydration buffers (8M Urea, 2% 
CHAPS, 50mM DTT, 0.2% Ampholytes, 0.002% Bromophenol Blue) were added to resolve 
the protein pellet. The dissolved protein samples were loaded underneath the 11cm 3-10 
ReadyStripTM IPG strips (Bio-Rad), and covered with mineral oil for a 12-14 h sample 
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absorption at RT. A 4-5 h isoelectric focusing was later carried out on Ettan IPGphor3 
Dedcated IEF system (GE Healthcare) with recommended protocol. After equilibration to 
resolubilize proteins and reduce disulfide bonds, the second dimensional electrophoresis was 
performed with 10% SDS-PAGE. CHO/IR/IRS1 cell lysate was used as positive control for 
the following IRS1 western blotting detection.  
 
Glucose uptake assay – Differentiated 3T3-L1 cells at Day 9 in 24-well plates were 
changed with various treatment media including 10% FBS for 18 h. For serum starvation, the 
cells were rinsed 3 times with PBS and incubated in a 0.5% FBS, 25mM HEPES treatment 
media for another 2 h. After being washed with freshly made KRBH buffer for 3 times, the 
cells were incubated with 0.1% FBS in KRBH for 20 min. 100nM insulin, 0.1 N HCl control 
as well as 20 µM cytochalasin B (Sigma) control were added into the incubation media for 
another 10 min to perform insulin stimulation followed with 0.5 µCi 1-[3H]-2-DG 
(PerkinElmer) added into the media for another 5 min incubation. To remove the excess 
glucose and halt the uptake process, the cells were washed with cold PBS for 3 times, and 
immediately lysed with 0.4ml 1% SDS for 10 min at RT on shaker to accelerate extracting 
the cell layers into the lysis buffer. The whole cell lysate were then transferred into 4 ml 
scintillant and 1-[3H]-2-DG uptake was measured using Beckman LS650 scintillation counter. 
Nonspecific deoxyglucose uptake was measured in the presence of cytochalasin B and was 
subtracted from the total glucose uptake readout.   
 
In vitro ncOGT labeling – Recombinant ncOGT was purified as previously described 
and saved as 20% glycerol stock at -20°C [14].  Immunoprecipitated mIRS1-beads from 
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293T cells were mixed with 1 µl 1 Unit/µl Calf intestinal alkaline phosphatase (CIP, NEB), 1 
µg ncOGT, 1 µl 200mM UDP-GlcNAc and 50mM HEPES, pH 7.6 to make 20 µl reaction 
mixture. The reaction mixture was then placed on rotator for 2 h incubation at RT. Reaction 
was terminated by washing the beads with 1% NP-40 buffer once to remove the excess OGT 
and CIP. 20ul 6x SDS loading buffer was added later to extract the ncOGT labeled mIRS1 
from magnetic beads for SDS-PAGE analysis.  
 
Peptide digestion and LC-MS/MS - ncOGT labeled mIRS1 samples were resolved by 
SDS-PAGE and stained with Coomassie G-250. mIRS1 bands were collected and in-gel 
digested with previously published protocol [15] . The bands were sliced into tiny pieces and 
destained by 25mM (NH4)HCO3 in 70% acetonitrile (ACN) , and then reduced by 0.1 M 
DTT, followed by 55mM iodoactamide reaction. The reduced mIRS1 protein was later 
digested with trypsin (Promega) overnight. The digested peptides were extracted from the 
sliced gels by repeating treatments with 5% formic acid ad 50% acetonitrile. All the 
extractions were combined into one tube and dried down under a speed vacuum. The 
peptides were then cleaned up by C18 spin column (Nest Group) to remove the remaining 
salts.  
The salt-free peptides were separated into 2 parts, and analyzed by both CID and 
ETD fragmentation modes in mass spectrometer. The mass spectrometer was linked with an 
online auto sampler and a reverse-phase nano-2D liquid chromatography (LC) system 
(Eksigent Technologies).  The LTQ-orbitrap Velos mass spectrometer was operated to 
capture both precursor and daughter ions with high resolution (Thermo Scientific).  The LTQ 
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was programmed to record a full precursor scan (m/z: 350-1800) followed by fragmentation 





OGT and OGA inhibitor treatment induce negative feedback regulation on the 
enzymes –Differentiated 3T3-L1 cells were treated with OGT or OGA inhibitors. First of all, 
the treatment condition was optimized and the treatment effects were confirmed by SDS-
PAGE western blotting using pan specific O-GlcNAc antibody. We incubated differentiated 
3T3-L1 cells in 4 different groups of culture media. Each group of cells was treated with 
control, specific OGA inhibitor TMG, specific OGT inhibitor AcSG and unspecific OGA 
inhibitor PUGNAc, which not only inhibits OGA, but also inhibits lysosomal 
hexoaminidases.  We observed the obvious changes in cellular O-GlcNAcylation under OGT 
and OGA inhibition (Figure 6). We also observed increased OGT expression when OGT was 
inhibited, and elevated OGA expression when OGA was inhibited in all four media 
conditions. Through this negative feedback regulation on OGT and OGA protein expression, 
the stress caused by dramatic changes in cellular O-GlcNAcylation can be partially 
diminished. O-GlcNAc cylcling is highly involved in epigenetic regulation of gene 
expression as well as regulation of protein expression, via targeting various transcriptional 
factors, histones, ribosomal proteins and proteasomes [16].  As for the detailed mechanism of 
elevated OGT and OGA expression, more investigation needs to be done.  
 
OGT and OGA inhibitors activate different branches of the insulin signaling 
pathways in 3T3-L1 cells – By altering cellular O-GlcNAcylation via inhibiting O-GlcNAc 
cycling in 3T3-L1 cells, we studied the crosstalk of O-GlcNAcylation and phosphorylation 
within insulin signaling pathway. With more than ten substrates identified for insulin 
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receptor tyrosine kinase, insulin impacts not only glucose, protein and lipids metabolism but 
also cell proliferation and differentiation. Activation of the INS/IRS/PI3K/AKT signaling 
cascade increases the translocation of GLUT4 to the plasma membrane and accelerates 
glucose uptake. In contrast, activation of INS/IRS or Shc/Grb2/RAS/RAF/ERK arms of the 
pathway leads to the proliferative effects of insulin, but with less impact on insulin’s anabolic 
effects. For the cell lysates collected in the various inhibitor treatments, we measured site-
specific phosphorylation on AKT, ERK and GSK3αβ by western blotting.  
Phosphorylation of Threonine 308 and Serine 473 are required for full activity of 
AKT. Phosphorylation of Threonine 308 is the key requirement for the kinase activation. 
Inhibition of OGT activity by AcSG boosted phosphorylation of Thr308 but not Ser473 on 
AKT under insulin stimulation (Figure 6). The phosphorylation boosting effect was 
consistent under all four media conditions (DMEM with 5mM and 25mM glucose, with and 
without 0.6nM insulin).  Co-incubation of 0.6nM insulin has been reported to gradually 
dampen insulin signaling in 3T3-L1 cells [9]. In our experiments, this effect was not obvious 
in cells grown in 5mM glucose. However, with high (25mM) glucose pre-incubation, in 
which 3T3-L1 showed relatively higher AKT activity, adding 0.6nM insulin did decrease 
phosphorylation of Thr308 on AKT and impair AKT activation. On the other hand, inhibition 
of OGA activity by TMG and PUGNAc did not cause significant difference on AKT activity 
compared with control group. This observation suggested the complexity of the crosstalk of 
O-GlcNAcylation and phosphorylation. Even though inhibition of OGT and OGA activity 
caused opposite affects on overall O-GlcNAcylation in 3T3-L1 cells, the affects on specific 
protein is not simply the opposite. 
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ERK1 and ERK2 regulate gene expression through phosphorylating downstream 
kinases as well as transcription factors; they also induce tRNA and rRNA synthesis to 
regulate protein expression. ERK1 and ERK2 share 90% sequence identity and both are 
expressed in adipocytes. Phosphrylation at both Threonine 202 and Tyrosine 204 sites on 
ERK1 and Threonine 185 and Tyrosine 187 on ERK2 are required for significant ERK 
activation with tyrosine residue proceeding threonine. Using the same 3T3-L1 cell lysate, we 
tested the activity of ERK1/2 through SDS-PAGE and blotted with site-specific 
phosphorylation antibody (Figure 6). Compared with no effects on ERK activity under AcSG 
pretreatment, specific inhibition of OGA by TMG treatment resulted in higher ERK activity 
under insulin stimulation. Our result provided a possible molecular mechanism to a previous 
report about inhibition of OGA does not induce insulin resistance in 3T3-L1 adipocytes [8]. 
Meanwhile, glucose concentration as well as physiological amount (0.6nM) of insulin in the 
incubation media did not affect ERK activity, as we expected.   
As a downstream signaling molecule of AKT, GSK3αβ are phosphorylated and 
deactivated, thus stimulates glycogen synthesis by activating glycogen synthase. Considering 
the very low glycogen levels in adipose tissue, GSK3αβ is more associated with adipogenesis 
through phosphorylating transcription factor CCAAT/enhancer binding protein α (C/EBPα). 
Similar to previously report in neuroblastoma cells Neuro 2a [17], no change on GSK3αβ 
activity, as shown by using the specific antibody against GSK3αβ at Ser21/Ser9, was 




Figure 6. O-GlcNAcylation regulates unique insulin signaling pathways. Differentiated 
3T3-L1 was switched to DMEM medium with low (5mM) or high (25mM) glucose, with or 
without physiological insulin (0.6nM). Different OGT or OGA inhibitors (C: control; T: 
TMG; Ac: AcSG; P: PUGNAc) were also added into the DMEM medium for coincubation. 
After serum starvation, the cells were stimulated with 100nM insulin for 15min. O-
GlcNAcylation, OGT and OGA levels were detected (A.), different downstream signaling 
pathways under insulin were tested: Akt pathway (B.), ERK pathway (C.), GSK pathway 
(D.). 
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OGT inhibitor AcSG pretreatment enhances AKT signaling under insulin resistance  - 
With the observation of OGT inhibition resulted in elevated AKT activity in 3T3-L1 
regardless of glucose concentration as well as the existence of physiological insulin, we 
decided to further test AKT activity under induced insulin resistance condition, which has a 
relative low insulin stimulated AKT activity. A number of studies have demonstrated that 
tumor necrosis factor α (TNFα) pretreatment causes insulin resistance via loss of IRS1 and 
GLUT4 expression, and enhancement of serine phosphorylation on IRS1 [18, 19].  Based on 
Figure 6, enhanced AKT activity by OGT inhibition was most striking with high glucose 
DMEM incubation. We thus adopted the same media condition for TNFα pretreatment.  
Fully differentiated 3T3-L1 cells were pretreated with 10ng/ml TNFα for 4 hours before 
changing to 1% FBS media and coincubation with 10ng/ml TNFα (Sigma) and 50µM AcSG 
coincubation for another 18 hours. The cells were then serum starved with FBS free media 
for 2 hours before equilibrated with KRBH buffer for another 20 min. 100nM insulin was 
used to stimulate the cells for 15 min, and the whole cell lysate was subjected for SDS-PAGE 
and western blot. In Figure 7, as expected, compared with control treatment, TNFα 
pretreatment resulted in lower IRS1 expression and low amount of Threonine 308 
phosphorylated AKT. Even TNFα pretreatment caused dampend AKT activity, AcSG 
coincubation with TNFα still had the highest AKT activity among the 4 types of 
pretreatments (Control vs TMG vs AcSG vs PUGNAc). All the above results shown in 
Figure 6 and Figure 7 suggest that partial OGT inhibition results in improved insulin 





Figure 7. OGT inhibition boosted INS/IRS/AKT pathway under insulin resistance 
condition.  WITH TNFα pretreatment, we mimicked insulin resistance on 3T3-L1 cell lines. 
The same OGT and OGA inhibition as Figure 6. were added into high glucose DMEM 
medium. The intensity of AKT signaling under insulin stimulation was detected through 
western blotting with anti-phospho Thr308-Akt antibody. 
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OGT inhibition greatly improved insulin stimulated glucose uptake in 3T3-L1 cells – 
In order to further demonstrate the possibility of using AcSG as a treatment for insulin 
resistance and Type II diabetes, we measured glucose uptake in 3T3-L1 cells under different 
treatments and media incubation. 3T3-L1 cells were incubated in 4 different media and 
treated with 4 conditions. As for 1-[3H]-2-DG uptake, the nonspecific glucose uptake 
measured through cytochalasin B treatment was subtracted to only compare the specific 
glucose uptake through glucose transporters. Figure 8 illustrated the specific glucose uptake 
in 3T3-L1 cells listed by treatment as well as by incubation media. Compared with basal state 
(cluster 1), acute 100nM insulin stimulation (cluster 2) significantly increased glucose uptake 
into the cells, no matter the glucose concentration or existence of low-dose insulin in the 
DMEM media. Notably, pretreatment with AcSG to inhibit OGT activity within cells 
resulted in even higher insulin-stimulated glucose uptake (cluster 3 and 4).  In addition, 
adding 0.6nM insulin in DMEM with both 5mM glucose and 25mM glucose impaired the 
glucose uptake at both basal state and insulin stimulated state. However, with AcSG 
pretreatment, this dampened glucose uptake effect was not present with 5mM glucose 
DMEM incubation, but only observed under high glucose DMEM incubation. In Figure 6, 
0.6nM insulin incubation caused more severe impairment on AKT activity.  This may be why 
we only observed decreased glucose uptake in high glucose DMEM media rather than in low 




Figure 8. Glucose uptake assay under OGT or OGA inhibition.  Same treatments as in 
Figure 6 were conducted  on differentiated 3T3-L1 cell lines. Through chasing with 
radiolabelled unmetabolised  2-DG, the glucose uptake level was compared by the remaining 
radioactivity in the cells. 
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Elevated O-GlcNAcylated IRS1in adipose tissue of high fat diet fed rats – With 
observation of crosstalk of phosphorylation and O-GlcNAcylation in insulin signaling, we 
next studied the crosstalk between these two posttranslational modifications on specific 
protein IRS1. We found OGT and OGA inhibition boosted insulin stimulated AKT signaling 
and ERK signaling separately, which partially share the same upstream signaling molecule 
IRS. With OGT inhibition boosting insulin stimulated AKT signaling and glucose uptake, we 
further investigated the association of O-GlcNAcylated IRS1 with insulin resistance. For the 
past half century, a high fat diet has been proved to promote hyperglycemia and whole-body 
insulin resistance, and can be used to generate a valid rodent model for insulin resistance [20]. 
After feeding randomly grouped rats (n=3 for normal diet and n=3 for high fat diet) for 3 
months, the abdominal fat pad tissue was collected for immunopreciptation of IRS1 and 
western blot with O-GlcNAcylation antibody 110.6. We found significantly elevated O-
GlcNAcylated IRS1 on adipose in high fat diet fed group (Figure 9). Meanwhile we did not 
find any significant difference on overall O-GlcNAcylation in fat tissue between these two 
diets fed rats. Another research group has reported no changes of O-GlcNAcylation in the 
muscle and liver tissue of mice on a normal diet and high fat diet [21]. All these findings 
once again indicate the complexity between O-GlcNAcylation and insulin resistance. They 




Figure 9. Elevated O-GlcNAcylated IRS1 is associated with HF-diet induced insulin 
resistance. 6 male SD rats were randomly assigned into control diet and HF diet group. After 
feeding with the diet for 3 months, the fat tissue was extracted and immunoprecipitated with 
IRS1 antibody. The O-GlcNAcylation level on IRS1 was then blotted with CTD 110.6 
antibody. 
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Phosphorylation spectrum of IRS1 under OGT and OGA inhibition in CHO/IR/IRS1 
cells – As an important upstream molecule in insulin signaling, IRS1 is exquisitely regulated 
through Yin –Yang phosphorylation. Serine phosphorylation serves as a negative regulator of 
insulin signaling while tyrosine phosphorylation on IRS1 positively regulates insulin 
signaling. Among all 1243 amino acids, IRS1 contains  ~270 Ser/Thr/Tyr residues, many of 
which could be subjected to phosphorylation or O-GlcNAcylation. In order to acquire an 
overall view of the phosphorylation spectrum changes under OGT and OGT inhibition, we 
used two-dimensional electrophoresis (2DE) combined with western blotting. Affected by 
the high isoelectric point (pI) and molecular weight (MW) of IRS1, and low abundance of 
endogenous IRS1, we failed to detect any IRS1 stain from 3T3-L1 cells lysate even after 
numbers of optimizations. We later switched to CHO/IR/IRS1 cells, which have more 
concentrated IRS1 in the cell lysate [22].   Figure 10 showed the IRS1 blot of 2DE from 
different cell lysate. The further to the left a spot locates, the more phosphorylation it 
contains. Row 1 showed the IRS1 blot from CHO/IR cell lysate. With very low endogenous 
IRS1 expression in CHO cells, it can be served as a negative control for IRS1 blot. As 
expected, we did not observe any IRS1 spot at row 1. Row 2 to Row 5 are IRS1 blot results 
for CHO/IR/IRS1 cells under OGT or OGA inhibition. The wide spread of IRS1 stain on row 
2 suggested the basal phosphorylation state of IRS1. With insulin stimulation (Row 3), we 
observed most of IRS1 spots moved towards the acidic side, which indicates 
hyperphosphorylation on IRS1. With TMG pretreatment and insulin stimulation, IRS1 was 
still under hyperphosphorylation.  However, when comparing row 4 with row 3, we can tell 
IRS1 slightly transferred towards the basic end, except for a single hyperphosphorylation 
spot also found in basal state. OGT inhibition by AcSG induced a different phosphorylation 
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spectrum on IRS1 under insulin stimulation (Row 5). The IRS1 was shown as two clusters, 
one with hyper phosphorylation on the acidic side, the other is hypophosphorylation on the 
basic side. The unique phosphorylation spectrums on IRS1 under OGT and OGA inhibition  
demonstrated the extensive crosstalk of O-GlcNAcylation and phosphorylation once more, 




Figure 10.  OGT and OGA inhibition caused different phosphorylation spectrum on 
IRS1.  IRS1 overexpressed CHO/IR/IRS1 as well as the negative control CHO/IR cells were 
serum starved, and then treated with 100nM insulin for 15min. The total cell lysate were then 
precipitated to remove the ions. The pure protein pellet was then resolublized in equilibration 
buffer and absorbed into 11cm IPG strips. After running both dimensions, the protein sample 
was blotted with IRS1 antibody. The lefter a spot locate, the higher phosphorylation it 
indicates.
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O-GlcNAcylation of mouse IRS1 at Ser 635 and Ser 1005– With several O-
GlcNAcylation sites have been mapped on the C-terminus of rat and human IRS1, we 
decided to perform additional site mapping on mouse IRS1. One goal was to test whether the 
O-GlcNAcylation sites were conservative among species; the other one was to find more O-
GlcNAcylation sites. We overexpressed myc-tagged mouse IRS1 on 293T, and pulled down 
the IRS1 by anti-myc antibody. Figure 11 showed O-GlcNAcylation of overexpressed IRS1 
in 293T. By inhibiting O-GlcNAc cycling through TMG, O-GlcNAcylation of IRS1 has been 
increased. We also incubated the immunoprecipitated IRS1 with Clostridium perfringens 
NagJ (CpNagJ) in vitro, a close homologue to human OGA. The disappeared O-
GlcNAcylated IRS1 band proved our O-GlcNAcylation blot by the antibody CTD 110.6 was 
very specific.   
In order to increase the stoichiometry of O-GlcNAcylation on the IRS1 sample, 
besides treating 293T cells with TMG, we in addition in vitro OGT labeled the pulled down 
IRS1. Figure 11 was the O-GlcNAcylation blot for an aliquot of the IRS1 sample sending for 
site mapping. Compared with the left lane, IRS1 labeled by OGT in vitro had elevated O-
GlcNAcylation. The OGT labeled IRS1 sample was then run on SDS-PAGE, and followed 
with coomassie staining. All the IRS1 bands in SDS-PAGE was collected, trypsin digested 
and salt cleaned up. The digested peptides were sent for later mass spectrometry site mapping 
by Dr. Akilesh Pandey laboratory.  
Combing CID and ETD MS/MS, we found 2 new O-GlcNAclation sites on mouse 
IRS1, Ser 635 and Ser 1005. Ser 1005 site has also been demonstrated with O-
GlcNAcylation on rat and human sample [11]. Figure 11 represented the MS/MS
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Figure 11. O-GlcNAc site mapping of mouse IRS1. Myc-tagged mouse IRS1 was 
overxpressed in 293T cells. TMG (A) and ncOGT labeling (B) increase the stoichiometry of 
O-GlcNAcylation on IRS1 (C, D). The immunoprecipitated IRS1 sample from TMG treated 
293T cells was sent for nc OGT in vitro labeling, and in gel digestion. The peptides were 
then analysed by CID (C) and ETD (D) for potential O-GlcNAcylation site. The MS 
spectrums of O-GlcNAcylation on Ser635 were shown here.         
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fragment spectrums of the precursor peptide containing Ser635.  From CID MS/MS shown in 
Figure 11, we detected b4, b9, b10 and b10 fragment ions with one O-GlcNAc group, 
demonstrated O-GlcNAcy locating on either one or both of the serine residues. In Figure 11, 
precursor with one GlcNAc group and z11 fragment ion without O-GlcNAc group were 
observed, which suggested O-GlcNAc was located on Ser 635 rather than Ser 637.  
 
OGT inhibition dampened phosphorylation of Ser632/635 on IRS1 – Besides the 
newly mapped O-GlcNAcylation on Ser635 of IRS1, phosphorylation on Ser 632/635 has 
been shown to play an important role in negatively regulating the metabolic effects of insulin.  
With two types of modification identified on Ser635, we were interested in the 
phosphorylation changes when we chemically change O-GlcNAcylation in 3T3-L1 cells. 
Figure 12 showed that phosphorylation and O-GlcNAcylation on IRS1 was not simply 
inhibitory to each other. OGA inhibition, causing elevated O-GlcNAcylation in cell lysate, 
did not affect phosphorylation of Ser632/635 significantly. However, OGT inhibition, with 
barely detected O-GlcNAcylation within cells, impaired phosphorylation of Ser632/635 on 
IRS1, which was a negative regulator of downstream AKT pathway. This finding was 
consistent with our findings in Figure 6: AcSG pretreatment rather than TMG pretreatment 




Figure 12. Phosphorylation cycling on Ser635 of IRS1 under OGT and OGA inhibition. 
Differentiated 3T3-L1 cells were serum starved in high glucose DMEM, and treated with 
control, TMG or AcSG before stimulated with 100nM insulin for the certain time course 
(0,5,15,30,60 min). The cell lysate were analyzed by specific phosphorylation antibody for 
Ser632/Ser635. 
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O-GlcNAcylation on Ser635 negatively regulate O-GlcNAcylation on the C-terminus 
of IRS1 – With the observation of decreased O-GlcNAcylation on Ser635 and decreased 
phosphorylation on Ser632/635 under OGT inhibition, we further investigated the function of 
O-GlcNAcylation of Ser635 on IRS1. Figure 13 showed the effect on IRS1 O-
GlcNAcylation when mutated Ser635 to Ala or Glu. We were expecting a decreased or 
unchanged O-GlcNAcylation on site mutated IRS1, but observed increased O-
GlcNAcylations on Ser 635A and Ser635E mutated IRS1. Ser635E-IRS1, mimics of 
phosphorylated IRS1 on Ser635-IRS1, facilitated O-GlcNAcylation on other sites. Ser635A-
IRS1, with no O-GlcNAcylation or phosphorylation on this site, furtherly elevated O-
GlcNAcylation on IRS1.  Combing these two results together, we hypothesized that O-
GlcNAcylation on Ser635-IRS1 may act as a negative regulator of O-GlcNAcylation on 
other sites. Considering all other currently identified O-GlcNAcylation sites are located on 
C-terminus, we next tested the crosstalk of O-GlcNAcylation on Ser635 and O-
GlcNAcylation at the C-terminus.  
We made a C-terminal truncated IRS11-900 constructs with Ser635, Ser635A and 
Ser635E. When comparing the O-GlcNAcylation of this truncated IRS1 and the full-length 
IRS1 (Figure 13), we found a dramatical decrease of O-GlcNAcylation on IRS1, suggesting 
the main O-GlcNAcylation sites on IRS1 locate at the C-terminus. The faint O-
GlcNAcylation blot on Ser635A- IRS11-900  suggested other O-GlcNAcylation sites exist 
besides Ser635 on the truncated IRS1. We also reconfirmed O-GlcNAcylation on Ser635 in 
the truncated IRS1 form. With Ser 635 mutated into Ala and Glu, O-GlcNAcylation of 






Figure 13. Crosstalk between O-GlcNAc on Ser635 and C-terminal O-GlcNAc residues 
on IRS1.  (A) Total O-GlcNAcylation level on the overexpressed IRS1 in 293T cells were 
measured on the wild type (WT), Ser635A and Ser635E mutants. (B). A C-terminus 
truncated IRS1 (900-IRS1) was compared with full length (FL-IRS1) in the overall O-
GlcNAcylation level, p85 alpha binding with IRS1 among WT, Ser635A and Ser635E 
mutants.  (C). The proposed model of the function of O-GlcNAcylation on Ser635 of IRS1. 	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C-terminal O-GlcNAcylation is reported to inhibit nearby tyrosine phosphorylation, 
which act as the docking sites for PI3K. With C-terminus truncated, we detected the binding 
between IRS11-900  and PI3K. To our surprise, we found a much stronger binding between 
PI3K and the truncated IRS11-900. The reasons for this observation could be: first: tyrosine 
phosphorylation on IRS11-900 (such asY608, 628) are the main docking site for IRS1. The 
other would be with the overall effect of C-terminal O-GlcNAcylation and phosphorylation 
on IRS1 is inhibitory to PI3K binding.  We then compared the PI3K binding with IRS1 
among Ser635, Ser635A and Ser635E. With elevated overall O-GlcNAcylation on Ser635A-
FL-IRS1, we observed decreased PI3K binding, consistent with the negative regulation of 
PI3K binding by the C-terminal O-GlcNAcylation.  The decreased binding with PI3K 
through Ser635A mutation disappeared on IRS11-900 , since in the truncated IRS1, O-
GlcNAcylation on Ser635 lost its inhibitory crosstalk with the C-terminal O-GlcNAcylation.  
Our model of O-GlcNAcylation on IRS1 is summarized in Figure 13, with extensive 
crosstalk between phosphorylation and O-GlcNAcylation, among O-GlcNAcylations  and 












O-GlcNAcylation and phosphorylation are two rapidly cycling posttranslational 
modifications both occuring on Serine and Threonine residues. Large-scale proteomics 
studies suggested O-GlcNAcylation and phosphorylation could function both synergistically 
and antagonistically [23]. Insulin stimulates phosphorylation on different signaling molecules, 
thus regulates various cellular processes, including glucose metabolism and cell growth. 
Disordered insulin signaling is highly associated with disease development, such as type II 
diabetes and cancer. Herein, we further explored the crosstalk of O-GlcNAcylation and 
phosphorylation in insulin signaling, mainly focused on how O-GlcNAcylation affects 
glucose metabolism related insulin signaling.  
Many controversies exist on the association of O-GlcNAcylation with type II diabetes 
and insulin resistance [24].  Glucosamine treatment, GFAT and OGT overexpression caused 
insulin resistance. On the other hand, specific OGA inhibitor treatment, OGA overexpression 
and OGT knockdown did not cause insulin resistance in other models. In our research, we 
found OGT and OGA inhibition caused negative regulation on OGT and OGA protein 
expression, and revealed the difference between genetic and pharmacological regulation of 
O-GlcNAcylation. Our data showed OGT and OGA inhibition, respectively each boosted 
different  insulin stimulated signaling cascades. The fact that OGA inhibition did not affect 
INS/IRS/AKT signaling pathway, is consistent with previous observation that a very specific 
OGA inhibitor did not induce insulin resistance.  
The effect of OGT inhibition on 3T3-L1 cells has never been studied. With the 
development of an OGT inhibitor [12], we studied its pharmacological effect on 3T3-L1. We 
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demonstrated the potential for inhibitors like AcSG to ameliorate insulin resistance and type 
II diabetes. AcSG treatment of 3T3-L1 dramatically boosted insulin stimulated AKT 
signaling pathway, under various incubation conditions, such as low glucose, high glucose, 
+/- low-dose insulin in the culture media.  Under insulin resistance induced by TNFα on 3T3-
L1, AcSG’s effect on the AKT signaling still occurred. Consistent with the effect of elevated 
AKT activity, AcSG also dramatically increased glucose uptake in 3T3-L1 cells. Our data 
systematically presented the potential usage of treating type II diabetes with OGT inhibitors, 
such as AcSG. Considering we only tested the effect of AcSG on adipocytes, more studies on 
muscle and liver and animals are required to evaluate the usefulness of OGT partial 
inhibition in treatment for diabetes.  
We also showed the crosstalk of O-GlcNAcylation and phosphorylation on IRS1, 
which can be extensively phosphorylated on serine and tyrosine residues to regulate insulin 
signaling. With showing high fat diet induced insulin resistant rat had elevated O-
GlcNAcylated IRS1 level on fat tissue, we were inspired to study the effect of O-
GlcNAcylated IRS1 in the development of insulin resistance. With IRS1 located upstream of 
both AKT and ERK signaling pathways, and since OGT and OGA inhibition specifically 
boosted AKT and ERK activity, we first measured the phosphorylation status of IRS1 under 
OGT and OGA inhibition. 2DE blot revealed OGT and OGA pretreatments caused distinct 
phosphorylation patterns on IRS1, which may be linked with the activation of unique insulin 
stimulated signaling pathways.  AcSG pretreatment induced a “two-clustered” 
phosphorylation pattern on IRS1 under insulin stimulation, which indicated 
hyperphosphorylation and hypophosphorylation coexist on IRS1. TMG pretreatment caused 
hyper phosphorylation on IRS1 under insulin stimulation, including an extreme 
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phosphorylation also shown in basal condition. More details about the insulin stimulated 
phosphorylation on IRS1 under OGT and OGA inhibition can be revealed through SILAC 
experiments. Clarified site-specific phosphorylation changes on IRS1 would help us figure 
out how phosphorylation on IRS1 regulates the recruitment of different downstream 
signaling molecules.  
Previous literature showed O-GlcNAcylation occurred at the C-terminus of IRS1. Our 
research further confirmed this with mapping O-GlcNAcylation of Ser1005 on mouse IRS1as 
the homologous residues on rat and human IRS1. In addition, we found another O-
GlcNAcylation on Ser635 residue, which was considered to be one of the most important 
phosphorylation sites in regulating insulin signaling. Depending on the upstream kinases, the 
phosphorylation on Ser635 has been indicated in either upregulating or downregulating 
insulin signaling. The mammalian target of rapamycin (mTOR)/p70S6K phosphorylates 
Ser632/635 residues and negatively regulate insulin signaling [25]. While Rho-kinase (ROK) 
phosphorylated Ser632/635 caused significantly increased insulin-stimulated tyrosine 
phosphorylation, IRS1 binding to p85 subunit of PI3K as well as IRS1 associated PI3K 
activity [26]. With only one enzyme regulating O-GlcNAcylation, we were interested in 
identifying the O-GlcNAcylation effect on Ser635 of IRS1. 
Elevated O-GlcNAcylation on Ser635Ala-IRS1 indicated the crosstalk of O-
GlcNAcylation among Ser635 and other potential sites. The crosstalk may happen through 
structure inhibition or competitive OGT recruitment. With limited information on IRS1 
structure, it is hard for us to exclude either possibility. With all other documented O-
GlcNAcylation sites located on C-terminus, we further tested and confirmed the crosstalk of 
O-GlcNAcylation between Ser635 and C-terminal sites through using C-terminus truncated 
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IRS11-900. The elevated O-GlcNAcylation on Ser635A-FL-IRS1 did disappear onSer635A-
IRS11-900. As for IRS1 associated p85 binding, we found Ser635A mutation decreased the 
binding on full length IRS1 rather than C-terminus truncated IRS1. In addition, Ser635E 
mutation caused slight but not significant decrease of PI3K binding in both full length and 
truncated IRS1. In summary of the findings from site mutagenesis and protein truncation, we 
showed O-GlcNAcyaltion on Ser635 appears to negatively regulate O-GlcNAcylation on C-
terminus of IRS1, thus positively regulating PI3K binding and downstream signaling.  
Based on our study, we provided a general picture of how O-GlcNAcylation and 
phosphorylation interact with each other. Globally regulating O-GlcNAcylation level by 
OGT and OGA inhibition specifically regulated different insulin-stimulated signaling 
pathways, which may be explained by the various phosphorylation patterns on the signaling 
molecules. O-GlcNAcylation sites also interacts with each other on single protein, as shown 
in IRS1; O-GlcNAcylation on Ser635 acts as a positive regulator of insulin action through 
inhibiting other inhibitory O-GlcNAcylation. With phosphorylation also happening on the 
same residue, we discovered the elaborate regulation of signaling pathways through 
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